Corium International 10-K 15 Dec 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 11, 2014	Apr. 03, 2014
Document and Entity Information
Entity Registrant Name	Corium International, Inc.
Entity Central Index Key	1594337
Document Type	10-K
Document Period End Date	30-Sep-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$69.30
Entity Common Stock, Shares Outstanding		18,070,838
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$36,395	$13,581
Accounts receivable	4,168	3,129
Unbilled accounts receivable	1,385	1,495
Inventories, net	2,592	4,508
Prepaid expenses and other current assets	1,292	1,038
Total current assets	45,832	23,751
Property and equipment, net	12,658	12,622
Debt financing costs, net	571	902
Intangible assets, net	6,683	6,647
Notes receivable - related parties		100
TOTAL ASSETS	65,744	44,022
Current liabilities:
Accounts payable	2,512	2,748
Accrued expenses and other current liabilities	4,008	3,374
Bank line of credit		3,873
Long-term debt, current portion	107	457
Capital lease obligations, current portion	760	1,029
Preferred stock warrant liability		560
Recall liability, current portion	774	1,004
Deferred contract revenues, current portion	301	2,112
Total current liabilities	8,462	15,157
Long-term interest payable		11,590
Long-term debt, net of current portion	38,155	36,956
Convertible notes		9,399
Subordinated note		13,000
Subordinated note embedded derivative liability		7,367
Capital lease obligations, net of current portion	891	1,652
Recall liability, net of current portion	2,936	3,828
Deferred contract revenues, net of current portion	3,500	3,688
Total liabilities	53,944	102,637
Stockholders' equity (deficit):
Common stock, par value of $0.001 per share, 150,000,000 and 115,000,000 shares authorized; 18,003,883 and 1,881,177 shares issued and outstanding as of September 30, 2014 and 2013 respectively	18	2
Additional paid-in capital	114,117	-26,679
Accumulated deficit	-102,335	-92,423
Total stockholders' equity (deficit)	11,800	-119,100
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)	65,744	44,022
Convertible Preferred Stock
Current liabilities:
Convertible or Redeemable stock		57,261
Redeemable Common Stock
Current liabilities:
Convertible or Redeemable stock		$3,224

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Convertible or Redeemable stock, shares authorized		65,716,300
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	115,000,000
Common stock, shares issued	18,003,883	1,881,177
Common stock, shares outstanding	18,003,883	1,881,177
Convertible Preferred Stock
Convertible or Redeemable stock, par value (in dollars per share)	$0.00	$0.00
Convertible or Redeemable stock, shares authorized	5,000,000	65,716,300
Convertible or Redeemable stock, shares issued	0	36,034,900
Convertible or Redeemable stock, shares outstanding	0	36,034,900
Redeemable Common Stock
Convertible or Redeemable stock, par value (in dollars per share)	$0.00	$0.00
Convertible or Redeemable stock, shares issued	0	347,945
Convertible or Redeemable stock, shares outstanding	0	347,945

STATEMENTS_OF_OPERATIONS_AND_C

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Product revenues	$32,202	$38,704	$35,716
Contract research and development revenues	9,026	10,750	6,838
Other revenues	1,212	816	306
Total revenues	42,440	50,270	42,860
Costs and operating expenses:
Cost of product revenues	20,204	24,828	24,360
Cost of contract research and development revenues	15,391	11,856	10,244
Research and development expenses	7,365	5,496	3,966
General and administrative expenses	9,095	6,525	4,645
Amortization of intangible assets	547	541	512
Gain on disposal and sale and leaseback of equipment	-112	-177	-57
Total costs and operating expenses	52,490	49,069	43,670
Income (Loss) from operations	-10,050	1,201	-810
Interest income	7	9	4
Interest expense	-6,961	-7,705	-5,247
Change in fair value of preferred stock warrant liability	-274	-14	21
Change in fair value of subordinated note embedded derivative liability	7,367	-7,367
Other income			582
Loss before income taxes	-9,911	-13,876	-5,450
Income tax benefit (expense)	-1	-1	7
Net loss and comprehensive loss	-9,912	-13,877	-5,443
Net loss attributable to common stockholders, basic and diluted	($9,912)	($13,877)	($5,443)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	($0.99)	($6.24)	($2.47)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)	10,043,640	2,222,981	2,200,727

STATEMENTS_OF_CONVERTIBLE_PREF

STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Convertible Preferred Stock	Redeemable Common Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2011			$2,000	($27,990,000)	($73,103,000)	($101,091,000)
Balance at Sep. 30, 2011	57,261,000	3,367,000
Balance (in shares) at Sep. 30, 2011			1,793,189
Balance (in shares) at Sep. 30, 2011	36,034,900	363,383
Increase (Decrease) in Stockholders' Equity
Issuance of common stock warrants in connection with debt and capital lease financing				110,000		110,000
Repurchase of redeemable common stock and common stock from founders		-143,000
Repurchase of redeemable common stock and common stock from founders (in shares)		-15,438
Issuance of common stock upon exercise of stock options				12,000		12,000
Issuance of common stock upon exercise of stock options (in shares)			61,799
Stock-based compensation expense				66,000		66,000
Net loss and comprehensive loss					-5,443,000	-5,443,000
Balance at Sep. 30, 2012			2,000	-27,802,000	-78,546,000	-106,346,000
Balance at Sep. 30, 2012	57,261,000	3,224,000
Balance (in shares) at Sep. 30, 2012			1,854,988
Balance (in shares) at Sep. 30, 2012	36,034,900	347,945
Increase (Decrease) in Stockholders' Equity
Issuance of common stock warrants in connection with debt and capital lease financing				38,000		38,000
Issuance of common stock upon exercise of stock options				13,000		13,000
Issuance of common stock upon exercise of stock options (in shares)			26,189
Stock-based compensation expense				330,000		330,000
Modification of warrants issued in connection with debt				742,000		742,000
Net loss and comprehensive loss					-13,877,000	-13,877,000
Balance at Sep. 30, 2013			2,000	-26,679,000	-92,423,000	-119,100,000
Balance (in shares) at Sep. 30, 2013			1,881,177
Balance at Sep. 30, 2013	57,261,000	3,224,000
Balance (in shares) at Sep. 30, 2013	36,034,900	347,945
Increase (Decrease) in Stockholders' Equity
Decrease in equity associated with modification of subordinated debt				-3,485,000		-3,485,000
Issuance of common stock in connection with initial public offering, net of issuance costs of $2.70 million			7,000	48,452,000		48,459,000
Issuance of common stock in connection with initial public offering, net of issuance costs of $2.70 million (in shares)			6,874,997
Conversion of convertible preferred stock to common stock in connection with initial public offering	-57,261,000		4,000	57,257,000		57,261,000
Conversion of convertible preferred stock to common stock in connection with initial public offering (in shares)	-36,034,900		3,567,807
Issuance of common stock in connection with conversion of convertible debt			2,000	19,367,000		19,369,000
Issuance of common stock in connection with conversion of convertible debt (in shares)			2,036,555
Issuance of common stock upon conversion of subordinated debt in connection with the recapitalization transaction			3,000	19,234,000		19,237,000
Issuance of common stock upon conversion of subordinated debt in connection with the recapitalization transaction (in shares)			3,387,146
Issuance of common stock upon net exercise of preferred stock warrants and related extinguishment of preferred stock warrant liability				310,000		310,000
Issuance of common stock upon net exercise of preferred stock warrants and related extinguishment of preferred stock warrant liability (in shares)			1,191
Issuance of common stock upon net exercise of common stock warrants			1,000	-1,000		0
Issuance of common stock upon net exercise of common stock warrants (in shares)			970,249
Repurchase of redeemable common stock and common stock from founders		-3,224,000	-1,000	-2,001,000		-2,002,000
Repurchase of redeemable common stock and common stock from founders (in shares)		-347,945	-729,864
Issuance of common stock upon exercise of stock options				34,000		34,000
Issuance of common stock upon exercise of stock options (in shares)			14,650
Stock-based compensation expense				1,629,000		1,629,000
Aggregate fractional shares cancelled in connection with reverse stock split			-25
Net loss and comprehensive loss					-9,912,000	-9,912,000
Balance at Sep. 30, 2014			$18,000	$114,117,000	($102,335,000)	$11,800,000
Balance (in shares) at Sep. 30, 2014			18,003,883
Balance (in shares) at Sep. 30, 2014	0	0

STATEMENTS_OF_CONVERTIBLE_PREF1

STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (USD $)	0 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Apr. 08, 2014	Sep. 30, 2014
STATEMENTS OF CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
Issuance of common stock in connection with initial public offering, issuance costs	$2.70	$2.70

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss and comprehensive loss	($9,912)	($13,877)	($5,443)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	2,230	1,892	1,973
Gain on disposal and sale and leaseback of equipment	-112	-177	-57
Gain on settlement of recall liability			-582
Change in fair value of preferred stock warrant liability	274	14	-21
Change in fair value of subordinated debt embedded derivative liability	-7,367	7,367
Amortization of premium on modification of subordinated note	-292
Amortization of intangible assets	547	541	512
Noncash amortized issue costs on long-term debt and capital leases	331	329	706
Noncash amortized discount on long-term debt and capital leases	128	196	246
Write off of patent costs		82	101
Stock compensation expense	1,629	330	66
Non-cash reductions in recall liability prior to settlement			-3,041
Interest expense on convertible and subordinated notes converted to common stock	823
Changes in operating assets and liabilities:
Accounts receivable	-1,039	-329	889
Unbilled accounts receivable	110	672	-18
Inventories, net	1,916	-139	82
Prepaid expenses and other current assets	-255	-137	-563
Accounts payable	700	-878	-1,289
Accrued expenses and other liabilities	2,058	1,329	-176
Deferred contract revenues	-1,998	321	3,465
Recall liability	-1,122	-168
Long-term interest payable		1,650	3,190
Net cash provided (used) by operating activities	-11,351	-982	40
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	-3,221	-7,163	-1,859
Proceeds from sale of equipment	12	17	15
Issuance of notes receivable - related parties		-100	-49
Proceeds from repayment of notes receivable - related parties	100
Payments for patents and licensing rights	-584	-693	-467
Net cash used by investing activities	-3,693	-7,939	-2,360
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs	48,459
Repurchase of redeemable common stock from founders, in connection with initial public	-5,225
Proceeds from issuance of long-term debt		7,230	36,477
Proceeds from issuance of capital leases		2,266	84
Payments on convertible notes			-10,000
Payment of transaction costs associated with issuance of long-term debt		-112	-1,671
Principal payments on long-term debt	-484	-812	-8,792
Principal payments on capital lease obligations	-1,054	-629	-548
Borrowings on bank line of credit	1,298	5,827	24,706
Payments on bank line of credit	-5,170	-3,526	-26,276
Proceeds from exercise of stock options	34	13	12
Net cash provided by financing activities	37,858	10,257	13,992
NET INCREASE IN CASH AND CASH EQUIVALENTS	22,814	1,336	11,672
CASH AND CASH EQUIVALENTS - Beginning of period	13,581	12,245	573
CASH AND CASH EQUIVALENTS - End of period	36,395	13,581	12,245
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	4,669	4,856	766
Cash paid for income taxes	2
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock warrants in connection with debt financing and equipment lease financing		38	110
Property and equipment purchases included in accounts payable and accrued liabilities	198	1,134	806
Issuance of payment-in-kind notes in lieu of cash interest payments associated with long-term debt	1,305	1,235	161
Reduction in notes receivable through redemption of common stock			143
Unpaid deferred offering costs		20
Decrease in equity due to premium associated with modification of subordinated debt	3,485
Conversion of convertible preferred stock to common stock	57,261
Issuance of common stock upon conversion of subordinated debt	19,237
Issuance of common stock upon conversion of convertible debt	19,369
Issuance of common stock upon net exercise of preferred stock warrants	$834

Organization_Description_of_Bu

Organization, Description of Business, and Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2014
Organization, Description of Business, and Summary of Significant Accounting Policies
Organization, Description of Business, and Summary of Significant Accounting Policies	1. Organization, Description of Business, and Summary of Significant Accounting Policies
	Organization
	Corium International, Inc., a Delaware corporation (the "Company"), is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage its broad experience in transdermal and transmucosal delivery systems.
	In the normal course of business, the Company enters into collaboration agreements with partners to develop and manufacture products based on the Company's drug delivery technologies. Revenues consist of net sales of products manufactured, royalties and profit-sharing payments based on sales of such products by partners, and fees for research and development activities under collaboration agreements with our partners. The Company is also engaged in the research and development of its own proprietary transdermal drug delivery products.
	The Company's fiscal year ends on September 30. References to "fiscal" refer to the years ended September 30.
	Basis of Presentation
	The Company's financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.
	Reverse Stock Split
	On March 20, 2014, the Company effected a 1-for-10.1 reverse stock split of the Company's outstanding common stock resulting in a reduction of the Company's total common stock issued and outstanding from 19,032,056 shares to 1,884,362 shares. The reverse stock split affected all stockholders of the Company's common stock uniformly, and did not materially affect any stockholder's percentage of ownership interest. The par value of the Company's common stock remained unchanged at $0.001 per share and the number of authorized shares of common stock remained the same after the reverse stock split.
	In connection with this reverse stock split, the number of shares of common stock reserved for issuance under the Company's equity incentive, stock option and employee stock purchase plans, as well as the shares of common stock underlying outstanding stock options, restricted stock units and warrants, were also proportionately reduced while the exercise prices of such stock options and warrants were proportionately increased. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.
	Initial Public Offering
	On April 2, 2014, the Company's registration statements on Form S-1 (File No. 333-194279 and File No. 333-195002) relating to the Initial Public Offering (the "IPO") of its common stock were declared effective by the SEC. The IPO closed on April 8, 2014 at which time the Company sold 6,500,000 shares of its common stock at a price of $8.00 per share. The Company also granted the underwriters a 30-day option to purchase up to 975,000 additional shares of common stock at the IPO price. The underwriters exercised this option to purchase 374,997 shares on May 2, 2014. The Company received cash proceeds of $48.5 million from the IPO, including proceeds from the partial exercise of the underwriters' option, net of underwriting discounts, commissions and issuance costs paid by the Company, which totaled $2.7 million.
	On April 8, 2014, immediately prior to the closing of the IPO, all outstanding shares of convertible preferred stock converted into 3,567,807 shares of common stock, and the related carrying value of $57.3 million was reclassified to common stock and additional paid-in capital. In addition, certain warrants to purchase convertible preferred stock and common stock were also converted and net exercised into 971,440 shares of common stock. Upon the closing of the IPO, Corium also repurchased 1,077,809 shares of common stock from its founders, for an aggregate purchase price of $5.2 million.
	Following the filing of the Restated Certificate of Incorporation of the Company on April 8, 2014, the number of shares of capital stock the Company is authorized to issue is 155,000,000 shares, of which 150,000,000 shares may be common stock and 5,000,000 shares may be preferred stock. Both the common stock and preferred stock have a par value of $0.001 per share.
	Use of Estimates
	Estimates and assumptions are required to be used by management in the preparation of financial statements in conformity with accounting principles generally accepted in the United States of America that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of operating revenues and operating expenses during the reporting period. Those estimates and assumptions affect revenue recognition and deferred revenues, impairment of long-lived assets, determination of fair value of stock-based awards and other debt and equity related instruments, and accounting for income taxes. As future events and their effects cannot be determined with precision, actual results could differ from those estimates.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents with a single domestic financial institution that is well capitalized. The Company provides credit, in the normal course of business, to its partners and performs credit evaluations of such partners.
	Four partners accounted for 95%, 99% and 94% of the Company's revenues for fiscal 2014, 2013 and 2012. These same partners accounted for 95% and 100% of accounts receivable as of September 30, 2014 and 2013.
	Revenue Recognition
	The Company generates revenues from agreements for the development and commercialization of its products. The terms of the agreements may include nonrefundable upfront payments, partial or complete reimbursement of research and development costs, milestone payments, product sales, and profit sharing and royalties on product sales made by the partners. The Company recognizes revenues when the following criteria are met: persuasive evidence of a sales or service arrangement exists; delivery has occurred; the price is fixed or determinable; and collectability is reasonably assured.
	Revenue related to multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. This determination is generally based on whether any deliverable has stand-alone value to the partner. This analysis also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting. The selling price used for each unit of accounting is based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific nor third-party evidence is available. Typically, the Company has not granted licenses to partners at the beginning of its arrangements and, thus, there are no delivered items separate from the research and development services provided. As such, upfront payments are recorded as deferred revenues in the balance sheet and are recognized as contract research and development revenues over the estimated period of performance that is consistent with the terms of the research and development obligations contained in the agreement. The Company periodically reviews the estimated period of performance based on the progress made under each arrangement.
	Amounts related to research and development funding are generally recognized as the related services or activities are performed in accordance with the contract terms. To the extent that agreements specify services are to be performed on a cost-plus basis, revenues are recognized as services are rendered. Such work is generally billed on a monthly basis for time incurred at specified rates in the agreements. To the extent that agreements specify services to be performed on a fixed-price basis, revenues are recognized consistent with the pattern of the work performed. Generally, all of the agreements provide for reimbursement of third-party expenses, and such reimbursable expenses are billed as revenues as incurred.
	The arrangements may include contractual milestones, which relate to the achievement of pre-specified research, development, regulatory and commercialization events. The milestone events contained in the Company's arrangements coincide with the progression of the Company's product candidates from research and development, to regulatory approval and through to commercialization. The process of successfully developing a new product, having it approved from a regulatory perspective and ultimately sold for a profit is highly uncertain. As such, the milestone payments that the Company may earn from its partners involve a significant degree of risk to achieve. Research and development milestones in the Company's strategic alliances may include the following types of events: completion of pre-clinical research and development work, completion of certain development events and initiation of clinical trials. Regulatory milestones may include the following types of events: filing of regulatory applications with the Food and Drug Administration and approval of the regulatory applications by the Food and Drug Administration. Commercialization milestones may include product launch. The Company recognizes milestone payments in the period in which the performance obligation underlying the milestone is achieved.
	Upon commercialization, revenues are generated from product sales, royalties and profit sharing. Product sales are generally recognized as products are shipped and title and risk of loss pass to the partner. Royalties and profit sharing are generally recognized when the Company's partners sell the product to their customers and are based on a percentage of the Company's partners' net sales or net profits for products subject to our agreements. Product sales and royalty income are presented collectively as product revenues. Royalties and profit sharing totaled $6.7 million, $7.8 million and $6.4 million for fiscal 2014, 2013 and 2012.
	Other revenues consists of income derived from the Company's arrangements with its partners, whereby a portion of the revenues received under these agreements relates to rental income from embedded leases associated with manufacturing equipment and facilities specific to these relationships, as well as revenues associated with licenses granted to a third party for intellectual property related to a discontinued product.
	Research and Development
	Research and development expenses primarily comprise salaries and benefits associated with research and development personnel, overhead and facility costs, pre-clinical and non-clinical development costs, clinical trial, and related clinical manufacturing costs, contract services, and other outside costs. Research and development costs, including costs to be subsequently reimbursed under development contracts, are charged to expense when incurred.
	Advertising Costs
	The Company's advertising expenses were immaterial for fiscal 2014, 2013 and 2012.
	Stock-Based Compensation
	The Company accounts for stock-based compensation for all share-based awards made to employees and directors, including employee stock options and employee stock purchases related to the employee stock purchase plan, by measuring the cost of awards of equity instruments based on the grant-date fair value of the award. The Company determines the fair value of such awards using the Black-Scholes option-pricing model (the "Black-Scholes model"), which incorporates certain assumptions as follows:
	Expected Term—The expected term represents the period that the stock-based awards are expected to be outstanding before exercise or cancellation. As the Company's historical share exercise experience did not provide a reasonable basis upon which to estimate expected term because of a lack of sufficient data points, the Company estimated the expected term by using the simplified method.
	Risk-Free Interest Rate—The risk-free interest rate is based on the implied constant maturity yield currently available on U.S. Treasury issues with a maturity consistent with the expected term.
	Expected Volatility—Because the Company has limited information on the volatility of its common stock due to a lack of significant trading history and limited historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of comparable publicly traded companies. In evaluating comparability, the Company considered factors such as industry, stage of life cycle and size. The Company will continue to analyze the historical stock price volatility and term assumptions as more historical data for the Company's common stock becomes available.
	Expected Dividend—The Company does not anticipate declaring dividends in the foreseeable future.
	The Company recognizes compensation expense for the portion of share-based awards that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.
	Income Taxes
	The Company accounts for income taxes based on the liability method. Under the liability method, deferred tax assets and deferred tax liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and deferred tax liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and deferred tax liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized.
	Comprehensive Income (Loss)
	During fiscal 2014, 2013 and 2012, the Company did not recognize any other comprehensive income (loss) and, therefore, the net income (loss) and comprehensive income (loss) was the same for all periods presented.
	Net Loss per Share Attributable to Common Stockholders
	The Company calculates its basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for companies with participating securities. The Company's basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of the diluted calculation, convertible preferred stock, options to purchase common stock and common stock warrants are considered common stock equivalents but are excluded from the calculation of diluted net loss per share attributable to common stockholders if their effect is antidilutive.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company generally invests funds that are in excess of current needs in high-credit-quality instruments, such as obligations of U.S. government agencies and money market funds.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are stated at invoiced amounts. An allowance for doubtful accounts is established as needed based on a specific assessment of all invoices that remain unpaid following normal partner payment periods. All amounts deemed to be uncollectible are charged against the allowance for doubtful accounts in the period that the determination is made. The allowance for doubtful accounts was $0 as of September 30, 2014 and 2013.
	Inventories
	Inventories are stated at the lower of cost, on a first-in, first-out basis, or market. The Company records an allowance for excess and obsolete inventory based on anticipated obsolescence, usage, and historical write-offs.
	Property and Equipment
	Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Equipment is depreciated over its useful life, ranging from 3 to 8 years using the straight-line method. Leasehold improvements are depreciated or amortized over the shorter of the lease term or their useful lives ranging from 3 to 15 years using the straight-line method. Expenditures for maintenance and repairs are charged to expense as incurred.
	Capital Leases
	The Company leases several pieces of equipment under capital lease arrangements. During the year ended September 30, 2011, the Company completed two transactions, whereby existing manufacturing equipment was sold to and leased back from the lessor. Under these transactions, a gain on the sale was deferred and is being amortized over the life of the lease. Equipment leased under capital leases is amortized over the life of the lease term using the straight-line method.
	Intangible Assets
	Intangible assets consist primarily of the cost of acquired patents and legal costs associated with patent development and contract acquisition costs. These costs are capitalized and amortized on a straight-line basis over the lesser of the estimated economic lives of the patents or the underlying contracts and the remaining legal lives of the patents, which approximates the consumption over the estimated useful lives of the assets, once a patent is granted. The Company periodically reevaluates the original assumptions and rationale utilized in the establishment of the carrying value and estimated lives of these assets.
	Impairment of Long-Lived Assets
	Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the assets and their eventual disposition. Measurement of an impairment loss for long-lived assets that management expects to hold and use is based on the fair value of the asset. No impairment was recorded for fiscal 2014, 2013 or 2012.
	Fair Value of Financial Instruments
	Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Assets and liabilities recorded at fair value in the financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows:
	Level I—Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
	Level II—Inputs (other than quoted prices included in Level I) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument's anticipated life.
	Level III—Unobservable inputs that are supported by little or no market activity, but are significant to the fair value of the assets or liabilities. They reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
	Convertible Preferred Stock Warrants
	Prior to their conversion into common stock on April 8, 2014 in connection with the Company's IPO, the Company accounted for certain warrants to purchase shares of convertible preferred stock as liabilities at fair value, as it had determined that some of these warrants were derivative instruments because they contained antidilution provisions that protected the holders from certain equity issuances at a price below the original issue price of the underlying security. The Company remeasured these warrants to fair value at each balance sheet date, and recognized any change in the fair value as a change in the warrant liability in its statements of operations and comprehensive loss. The Company estimated the fair value of these warrants at the respective balance sheet dates using the Option Pricing Model, or OPM, in fiscal 2012 and the Probability-Weighted Expected Return Model, or PWERM, thereafter. The Company used a number of assumptions to estimate the fair value, including the likelihood of various scenarios, the expected volatility, and the fair value of the underlying stock under each scenario.
Subordinated Note Embedded Derivative Liability
Prior to its conversion into common stock on April 8, 2014 in connection with the Company's IPO, the Company had an outstanding subordinated note that the Company had determined contained an embedded derivative instrument related to redemption and conversion features of the note. These features required bifurcation and separate accounting, and were accounted for as a liability. The embedded derivative liability was remeasured to fair value at each balance sheet date, with the corresponding gain or loss from the adjustment recorded in the statements of operations and comprehensive loss. The fair value of the embedded derivative was measured with the PWERM valuation methodology. Under this methodology, fair value is primarily driven by the assessment of the probability and timing of scenarios that could result in the redemption of the note prior to the note's maturity, which would trigger the payment of the additional amount equal to the outstanding principal of the subordinated note.
Recent Account Pronouncements
In February 2013, the FASB issued guidance which addresses the presentation of amounts reclassified from accumulated other comprehensive income. This guidance does not change current financial reporting requirements. Instead, an entity is required to cross-reference to other required disclosures that provide additional detail about amounts reclassified out of accumulated other comprehensive income. In addition, the guidance requires an entity to present significant amounts reclassified out of accumulated other comprehensive income by line item of net income if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. Adoption of this standard is required for periods beginning after December 15, 2013. This new guidance impacts how the Company reports comprehensive income only, and had no effect on the Company's results of operations, financial position or liquidity during fiscal 2014 and 2013.
In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, "Revenue from Contracts with Customers", Topic 606. This ASU affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in this ASU supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to illustrate the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization's contracts with customers. This ASU is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 15, 2016 for public companies. The Company is evaluating the effect, if any, on the Company's financial position and results of operations.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Sep. 30, 2014
Fair Value Measurements
Fair Value Measurements	2. Fair Value Measurements
	Financial assets and liabilities are recorded at fair value. Except as noted below, the carrying values of the Company's financial instruments, including cash equivalents, accounts receivable, and accounts payable, approximated their fair values due to the short period of time to maturity or repayment.
	The Company's financial instruments that are measured at fair value on a recurring basis as of September 30, 2014 and 2013, by level within the fair value hierarchy, are as follows (in thousands):
		As of September 30, 2014
		Level I			Level II		Level III			Total
	Financial Assets:
	Money market funds	$	36,019		$	—	$	—		$	36,019
	Total financial assets	$	36,019		$	—	$	—		$	36,019
		As of September 30, 2013
		Level I			Level II		Level III			Total
	Financial Assets:
	Money market funds	$	13,342		$	—	$	—		$	13,342
	Total financial assets	$	13,342		$	—	$	—		$	13,342
	Financial Liabilities:
	Preferred stock warrant liability	$	—		$	—	$	560		$	560
	Subordinated note embedded derivative liability		—			—		7,367			7,367
	Total financial liabilities	$	—		$	—	$	7,927		$	7,927
	The Company's Level III liabilities consist of a preferred stock warrant liability (see Note 11) and subordinated note embedded derivative liability (Note 8). The following table sets forth a summary of the changes in the fair value of the Company's Level III financial liabilities, which are measured on a recurring basis (in thousands):
		Year Ended
		September 30,
		2014			2013
	Beginning balance	$	7,927		$	546
	Change in fair value of preferred stock warrants		274			14
	Change in fair value of subordinated note embedded derivative liability		(7,367	)		7,367
	Extinguishment of preferred stock warrant liability		(834	)		—
	Ending balance	$	—		$	7,927
	The following financial instruments have carrying values which differ from their fair value as estimated by the Company based on market quotes for instruments with similar terms and remaining maturities (Level III valuation technique) (in thousands):
		As of September 30, 2014
		Carrying			Fair Value		Difference
		Value
	Long-term debt	$	38,262		$	40,357	$	2,095
	Total	$	38,262		$	40,357	$	2,095
		As of September 30, 2013
		Carrying			Fair Value		Difference
		Value
	Long-term debt	$	37,413		$	37,413	$	—
	Convertible notes		9,399			14,316		4,917
	Subordinated note		13,000			9,508		(3,492	)
	Total	$	59,812		$	61,237	$	1,425

Inventories

Inventories	12 Months Ended
	Sep. 30, 2014
Inventories
Inventories	3. Inventories
	Inventories consist of the following (in thousands):
		As of
		September 30,
		2014			2013
	Raw materials	$	1,268		$	2,410
	Work in process		898			1,546
	Finished goods		632			667
	Total inventories, cost		2,798			4,623
	Less inventory reserves		(206	)		(115	)
	Total inventories, net	$	2,592		$	4,508

Property_and_equipment

Property and equipment	12 Months Ended
	Sep. 30, 2014
Property and equipment
Property and equipment	4. Property and equipment
	Property and equipment consist of the following (in thousands):
		As of September 30,
		2014			2013
	Machinery and equipment	$	12,242		$	11,145
	Manufacturing equipment acquired under capital leases		2,341			1,825
	Transportation equipment		25			25
	Furniture and fixtures		995			928
	Computer equipment and software		535			401
	Leasehold improvements		3,658			3,145
	Land		210			210
	Construction in progress		6,849			8,843
	Total property and equipment, gross		26,855			26,522
	Accumulated depreciation and amortization		(14,197	)		(13,900	)
	Total property and equipment, net	$	12,658		$	12,622
	The Company recorded depreciation and amortization of property and equipment of $2.2 million, $1.9 million and $2.0 million during fiscal 2014, 2013 and 2012.

Intangible_Assets

Intangible Assets	12 Months Ended
	Sep. 30, 2014
Intangible Assets
Intangible Assets	5. Intangible Assets
	Intangible assets and related accumulated amortization consist of the following (in thousands):
		As of September 30,
		2014			2013
	Cost:
	Patents and trademarks	$	10,269		$	9,686
	Contract acquisition costs		1,672			1,677
	Total carrying value		11,941			11,363
	Accumulated amortization:
	Patents and trademarks		(3,756	)		(3,237	)
	Contract acquisition costs		(1,502	)		(1,479	)
	Total accumulated amortization		(5,258	)		(4,716	)
	Total intangible assets, net	$	6,683		$	6,647
	The Company amortizes its intangible assets related to issued patents over the estimated useful lives of the patents, ranging from 7 to 20 years. Amortization of issued patents, excluding impairments or abandonments, was $0.5 million, $0.5 million and $0.4 million in fiscal 2014, 2013 and 2012.
	The estimated remaining annual amortization expenses for issued patents and trademarks as of September 30, 2014 are as follows (in thousands):
	Year Ending September 30:	Amounts
	2015	$	584
	2016		584
	2017		584
	2018		584
	2019		584
	Thereafter		1,480
	Total	$	4,400
	Patents in process included in intangible assets were $2.1 million and $2.5 million during fiscal 2014 and 2013.
	The Company amortizes its intangible assets related to contract acquisition costs over their estimated useful lives, ranging from 4 to 15 years. Amortization of contract acquisition costs was $29,000, $65,000 and $66,000 in fiscal 2014, 2013 and 2012.
	The estimated remaining annual amortization expense for contract acquisition cost as of September 30, 2014 are as follows (in thousands):
	Year Ending September 30:	Amounts
	2015	$	29
	2016		29
	2017		29
	2018		29
	2019		29
	Thereafter		25
	Total	$	170

Notes_Receivable_Related_Parti

Notes Receivable - Related Parties	12 Months Ended
	Sep. 30, 2014
Notes Receivable - Related Parties
Notes Receivable - Related Parties	6. Notes Receivable—Related Parties
	Notes receivable as of September 30, 2013, consisted of an unsecured note payable by one of the executive officers of the Company. The note called for payment of one-half of the principal and accrued interest on December 28, 2015 and the remaining principal and interest on June 28, 2018. The note accrued interest at 1% below the prime rate, adjusted as of January 1 each year (an effective rate of 2.25% at September 30, 2013). The Company recognized less than $1,000 of related party interest income from this note in fiscal 2014 and 2013. The note was repaid in full in March 2014.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Sep. 30, 2014
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	7. Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities consist of the following (in thousands):
		September 30,
		2014		2013
	Vacation	$	1,747	$	1,680
	Bonus		1,235		900
	Warranty liability		284		—
	Employee stock purchase plan liability		305		—
	Legal and professional fees		5		339
	Other		432		455
	Total accrued liabilities	$	4,008	$	3,374

Debt

Debt	12 Months Ended
	Sep. 30, 2014
Debt
Debt	8. Debt
	The Company's outstanding debt was as follows (in thousands):
		As of September 30,
		2014		2013
	Bank line of credit	$	—	$	3,873
	Long-term debt		38,262		37,413
	Convertible notes		—		9,399
	Subordinated note		—		13,000
	Total		38,262		63,685
	Less current portion, consisting of bank line of credit and long-term debt		107		4,330
	Long-term portion	$	38,155	$	59,355
	Bank Line of Credit
	The bank line of credit was established with the Company's commercial bank on August 31, 2012. The line of credit provided for borrowings up to $6.0 million, was collateralized by a first security interest in cash, accounts receivable, and inventory, as well as a second security interest in all other assets of the Company. The line of credit expired on August 31, 2014 and has not been renewed. Advances under the line of credit were based on 80% of eligible accounts receivable. The line of credit beared interest at 0.25%, plus the bank's prime rate (an effective rate of 4.25% as of September 30, 2013), and provided for a minimum monthly interest charge of $5,000. The line of credit contained a minimum monthly liquidity covenant of $2.0 million of net cash on deposit with the commercial bank. The Company was continuously in compliance with this covenant from August 31, 2012 through the expiration date, August 31, 2014.
	Long-term Debt
	Long-term debt was as follows (in thousands):
		As of September 30,
		2014		2013
	Term loan agreement expiring June 30, 2017. See terms of the agreement below.
	Less discount of $76 and $103 as of September 30, 2014 and 2013	$	37,625	$	36,293
	Notes payable to lessor for tenant improvements. The note calls for monthly payments of principal and interest of $3 at an interest rate of 7% and is due April 2015		96		124
	Notes payable to lessor for tenant improvements. The note calls for monthly payments of principal and interest of $6 at an interest rate of 7% and is due November 2024		541		575
	Notes payable to finance Company insurance premiums. The note calls for monthly payments of principal and interest of $71 at an interest rate of 2.192% and was due March 2014		—		421
	Total		38,262		37,413
	Less current portion		107		457
	Long-term portion	$	38,155	$	36,956
	On July 13, 2012, the Company completed a $35.0 million term loan agreement with a financial investment fund. In August 2012 and December 2012, the Company drew down $29.0 million and $6.0 million under this agreement. The agreement required interest to be paid quarterly at a simple annual rate of 15%, and all outstanding principal be repaid in four equal quarterly payments beginning September 30, 2016. The agreement also contained a provision whereby the Company could choose to defer cash payment of 3.5% on the original outstanding principal for the first 11 quarterly interest payments by converting that portion of the interest otherwise due into additional notes under the agreement. As of September 30, 2014 and 2013, the Company had converted $2.7 million and $1.4 million of interest into additional notes (payment-in-kind notes). Amounts outstanding under the term loan agreement are collateralized by all of the Company's assets. The agreement contained a 1% fee on all draws and provided for a prepayment penalty on the outstanding principal if the Company chose to repay principal prior to maturity, or upon other specified events, including a change of control. The term loan agreement provided for financial covenants for minimum revenues and minimum liquidity, which the Company was in compliance with as of September 30, 2014 and 2013.
	This term loan agreement was amended and restated in November 2014 (see Note 21).
	Minimum principal payments on the Company's outstanding long-term debt, as of September 30, 2014 were as follows (in thousands):
	Year Ending September 30:	Amounts
	2015	$	107
	2016		9,439
	2017		28,296
	2018		46
	2019		49
	Thereafter		325
	Total	$	38,262
	Convertible Notes
	In 2008 and 2009, the Company issued convertible bridge notes (the "Convertible Notes") and warrant purchase agreements to several of the then-existing Series C preferred stock investors, whereby the Company raised a total of $20.0 million. On April 8, 2014, in connection with the closing of the IPO, all of the Convertible Notes, with an aggregate principal amount and accrued interest of $19.4 million, were converted into 2,036,555 shares of common stock. As originally issued, the Convertible Notes accrued interest at 10% per year and matured on the earliest of July 31, 2009, the consummation of a significant sale of assets of the Company outside the normal course of business, or upon an uncured event of default. Subsequently, the maturities of the Convertible Notes were initially extended to October 31, 2009, after which they became due. In connection with the closing of the $35.0 million term loan agreement in July 2012, the Company ratably repaid $10.0 million of principal on the Convertible Notes and further extended the maturity date of the Convertible Notes to July 1, 2017. Interest was not paid on the Convertible Notes since inception and is, therefore, presented as long-term accrued interest at September 30, 2013.
	The Convertible Notes were secured by all assets of the Company, with such security interest being subordinated to the security interest granted by the Company to its commercial bank and the $35 million term loan agreement. Pursuant to an intercreditor agreement the Company entered into in July 2013, the Company was not permitted to pay interest on these notes until maturity.
	The Convertible Notes also provided for an amendment of the voting agreement between the Company and the majority of its stockholders, pursuant to which one investor had the right to increase the maximum size of the board of directors to 11 and that same investor also had the right to appoint up to 6 of the directors. This investor never exercised either of these rights.
	The Convertible Notes also provided for the issuance of common stock warrants exercisable for a number of shares equal to 60% of the principal amount of the Convertible Notes, divided by the conversion price of the Convertible Notes, which was, initially, the original issue price of the Series C preferred stock. The warrants were only exercisable following conversion of the Convertible Notes into preferred stock and would have been exercisable for shares of common stock of the Company. As of September 30, 2012, the warrants had all been issued, each with an expiration date five years from the date of each corresponding Convertible Note's issuance (see Note 11).
	During fiscal 2013, the carrying value of the Convertible Notes was reduced by $0.6 million due to the recognition of value associated with the modification of common stock warrants issued in connection with the Convertible Notes.
	Subordinated Note
	In 2009, the Company issued a subordinated note (the "Subordinated Note") to one of the existing Series C preferred stock investors raising a total of $13.0 million. On April 8, 2014, in connection with the closing of the IPO, the Subordinated Note, with a principal amount, accrued interest and derivative liability totaling $19.2 million, was converted into 3,387,146 shares of common stock. The Subordinated Note accrued simple interest at 5% per year and had an original maturity of the earliest of June 30, 2010, the consummation of a significant sale of assets of the Company outside the normal course of business, or upon an uncured event of default. In connection with the closing of the term loan agreement during the year ended September 30, 2012, the maturity of the Subordinated Note was extended to July 1, 2017. Interest was never paid on the Subordinated Note since inception and is, therefore, presented as long-term accrued interest at September 30, 2013.
	If the Company had consummated a merger of the Company or a sale of all or substantially all of the Company's assets, or a significant asset sale prior to the full repayment of the Subordinated Note, then, at the written election of the subordinated note holder, the holder of the Subordinated Note would have been entitled to be repaid the entire outstanding balance under the Subordinated Note plus an additional amount equal to the outstanding principal under the Subordinated Note, plus all accrued interest. The Company determined that this feature is an embedded derivative requiring bifurcation and separate accounting. The fair value of this embedded derivative liability was $7.4 million as of September 30, 2013. The change in fair value was recorded to change in fair value of Subordinated Note embedded derivative liability.
	The Subordinated Note was secured by all assets of the Company, with such security interest subordinated to the security interest granted by the Company to both its commercial bank and the term loan agreement. Pursuant to an intercreditor agreement the Company entered into in July 2012, the Company was not permitted to pay interest on these notes until maturity.
	As part of the recapitalization described below, in December 2013 the Subordinated Note was modified to provide that in the event of a qualifying IPO or equity financing, the note would automatically convert into 3.4 million shares of common stock or the equivalent amount of preferred stock. As this represented a substantial modification of the debt, it was accounted for as an extinguishment. Accordingly, the book value of the debt prior to the conversion was removed from the financial statements and the fair value of the debt after the modification of $16.5 million, including the value of the conversion feature, was recorded. As the holder of the subordinate debt controlled the majority of our equity and could have appointed the majority of our board, the modification of the debt was considered a transaction with owners. Accordingly the difference between the book value of the debt prior to the modification and the fair value of the debt after modification was recorded as a $3.5 million reduction in additional paid-in capital.
	Recapitalization
	In December 2013, the Company entered into an amendment and conversion agreement with Essex Woodlands pursuant to which (i) the Company and Essex Woodlands amended the Convertible Notes held by Essex Woodlands and other investors to provide that they would automatically convert either into 2,036,555 shares of the Company's common stock immediately prior to the closing of an initial public offering of the Company's common stock or into 2,036,555 shares of the Company's Series C preferred stock immediately prior to the first closing of a qualified equity financing that occurred prior to the closing of an initial public offering of the Company's common stock, and the Convertible Notes would be terminated; (ii) the Company and Essex Woodlands amended the terms of the Subordinated Note to provide that it would automatically convert either into 3,387,146 shares of the Company's common stock immediately prior to the closing of an initial public offering of the Company's common stock or into 3,387,146 shares of a new series of the Company's preferred stock (with identical rights, preferences and privileges as the Company's Series C preferred stock, but with a liquidation preference of one times its original issue price) immediately prior to the first closing of a qualified equity financing that occurred prior to the closing of an initial public offering of the Company's common stock, and the Subordinated Note would be terminated; and (iii) Essex Woodlands agreed that it would effect the automatic conversion of all outstanding shares of the Company's preferred stock in connection with the completion of an initial public offering of the Company's common stock.
	Simultaneously, the Company also entered into a repurchase agreement pursuant to which the Company agreed to repurchase 1,077,809 shares of the Company's common stock from two of the Company's founders, for an aggregate repurchase price of $5.2 million. These repurchases would occur immediately prior to the earlier of the consummation of an initial public offering of the Company's common stock and the first closing of a qualified equity financing, and these repurchases would satisfy in full all of the Company's remaining obligations under the repurchase agreements (see Note 12).

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies
Commitments and Contingencies	9. Commitments and Contingencies
	Capital Leases
	Certain manufacturing equipment is accounted for as a capital lease and is included in property and equipment as of September 30, 2014 and 2013.
	Future minimum lease payments under capital leases, together with the present value of the net minimum lease payments as of September 30, 2014, are as follows (in thousands):
	Year Ending September 30,	Amounts
	2015	$	897
	2016		877
	2017		73
	Total minimum lease payments		1,847
	Less amount representing estimated executory costs (such as taxes)		—
	Net minimum lease payments		1,847
	Less amount representing interest		(185	)
	Present value of net minimum lease payments		1,662
	Less discount related to warrants		(11	)
	Capital lease liability		1,651
	Less current portion		(760	)
	Long-term portion	$	891
	Depreciation expense on equipment under capital leases was $1.0 million, $0.6 million and $0.6 million for fiscal 2014, 2013 and 2012. As of September 30, 2014 and 2013, there was $0 and $112,000 of unrecognized gain on sale of leased assets.
	Operating Leases
	The Company conducts certain operations using leased property and equipment. The property and equipment leases require the Company to pay certain property taxes, insurance, and maintenance expenses, and expire on dates ranging through 2025. Total rental expense on operating leases for fiscal 2014, 2013 and 2012 amounted to $1.7 million, $1.6 million and $1.4 million.
	Future minimum lease payments under operating leases that had initial or remaining lease terms in excess of one year from September 30, 2014 were as follows (in thousands):
	Years Ending September 30,	Amounts
	2015	$	1,284
	2016		735
	2017		603
	2018		611
	2019		623
	Thereafter		3,653
	Total	$	7,509
	Guarantees and Indemnifications
	The Company, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and pursuant to indemnification agreements with certain directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company's request in such capacity. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.
	The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance limits the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.
	Contingencies
	The Company may be subject to legal proceedings and litigation arising in the ordinary course of business. The Company will record a liability when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company expects to periodically evaluate developments in its legal matters that could affect the amount of liability that it has previously accrued, if any, and make adjustments as appropriate. Significant judgment is required to determine both likelihood of there being, and the estimated amount of, a loss related to such matters, and the Company's judgment may be incorrect. The outcome of any proceeding is not determinable in advance. Until the final resolution of any such matters that the Company may be required to accrue for, there may be an exposure to loss in excess of the amount accrued, and such amounts could be material. Management is not aware of any legal matters in which the final disposition is expected to have a material effect on the business. See Note 15 for further discussion regarding product liabilities.
	On August 3, 2012, a wrongful death lawsuit was filed in the U.S. District Court for the Northern District of Texas, Boudreaux vs. Corium International, Inc., et al, naming Actavis Inc. and Actavis South Atlantic LLC ("Actavis") and the Company as co-defendants. Plaintiffs have alleged a family member died in connection with the use of Fentanyl TDS manufactured by the Company and distributed and sold by Actavis. The amount of the damages has not been specified. For this pending suit, the Company has insurance coverage up to $10 million with a maximum liability of $50,000 of out-of-pocket expense. The Company does not believe that the case has merit and plans to defend against this claim.

Collaboration_and_Partner_Arra

Collaboration and Partner Arrangements	12 Months Ended
	Sep. 30, 2014
Collaboration and Partner Arrangements
Collaboration and Partner Arrangements	10. Collaboration and Partner Arrangements
	The Company has recognized the following revenues from its collaboration and partner agreements during fiscal 2014, 2013, and 2012 (in thousands):
		Years ended September 30,
		2014		2013		2012
	P&G	$	11,719	$	11,781	$	7,880
	Teva		13,550		16,683		11,350
	Actavis/Par		12,971		16,551		18,139
	Agile		1,976		4,904		3,014
	Other		2,224		351		2,477
	Total revenues	$	42,440	$	50,270	$	42,860
	The Procter & Gamble Company
	In 2005, the Company entered into a multi-faceted collaboration arrangement with The Procter & Gamble Company, or P&G.
	The relationship includes a world-wide license to P&G for the use of certain of the Company's technologies for products in specific fields in which P&G operates. P&G paid the Company a $3.0 million fee for the license, and the Company is entitled to receive additional milestone payments for each qualifying product that the Company develops for P&G. In 2008, the Company received a $2.0 million milestone payment for the first series of products developed by the Company. P&G's license from the Company is perpetual and irrevocable.
	The Company entered into a long term joint development agreement under which the Company performs numerous development activities for P&G based upon agreed-upon statements of work and budgets. The development work performed by the Company under this agreement is billed to P&G on a time and materials basis, at cost. The P&G joint development agreement expires on June 13, 2015.
	The Company also entered into a commercial supply agreement for the production of all products developed by the Company for P&G. The Company has developed and commercialized several products which are currently marketed and sold by P&G under the brand name Crest Advanced Seal Whitestrips, or Crest Whitestrips. Several additional products are currently being developed by the Company for P&G, which are expected to launch in 2015 and beyond. The Company's current supply agreement with P&G was amended during 2014 and will now expire on January 31, 2017.
	In addition to these agreements, and as part of the overall collaboration agreement, the Company also acquired certain patents from P&G in 2005. In exchange for the assignment of these patents, the Company issued 125,428 shares of our common stock as payment for the patents acquired.
	Teva Pharmaceuticals USA, Inc.
	In 2004, the Company entered into an arrangement with Barr Laboratories, or Barr, for four generic products. The Company entered into three separate agreements with Barr, one in 2006 and two in 2007, to develop and commercialize three additional products. In 2008, Teva Pharmaceutical Industries, Ltd., or Teva, acquired Barr. Following this acquisition, Teva discontinued four of these development programs. Of the remaining three programs, one has resulted in an approved product, Clonidine Transdermal Delivery System, (TDS), which is currently marketed by Teva, one has been approved by the FDA for which Teva is currently assessing the launch strategy and timing, and the third product is pending regulatory approval. Under the Company's current agreements with Teva, the Company is not eligible for additional milestone payments.
	Under the agreements, the Company receives compensation for developing the products, generally on a time and materials basis. Once the products are commercialized, the Company generates product sales to Teva with a cost-plus margin and receives a profit share based on net profits (as defined in the agreements) earned by Teva for each product.
	The term of each commercial agreement with Teva extends, on a product-by-product basis, through the last day of the tenth full calendar year following the launch date of each product, with automatic one-year renewals.
	Par Pharmaceutical, Inc.
	On May 11, 2002, the Company entered into an arrangement to pursue development and commercialization of a generic version of the transdermal fentanyl product with Abrika LLLP. In 2007, Abrika was acquired by Actavis, Inc. Under the agreements, the Company agreed to develop the product and to assist Actavis with the regulatory filing and ultimate approval of such product. In October 2012, Actavis divested this product to Par who assumed the various agreements. Under the Company's current agreements, the Company is not eligible for additional milestone payments.
	The commercial agreement with Par has a term of twenty years, and expires on November 12, 2023.
	In September 2014, the Company recognized $1.8 million in non-cash product revenues which had previously been deferred since 2007. The recognition of this revenue related to the expiration of a contractual liability under an agreement with Par, and will not have an impact on future revenues.
	Agile Therapeutics, Inc.
	In 2006, the Company entered into an arrangement with Agile to develop a new transdermal patch product using Agile's previously developed technology. Under the arrangement, the Company has performed process development activities and manufacturing of the product ("AG200-15"). For the development work performed, Agile paid the Company in several ways, including time and materials and milestones for achievement of certain development goals. During fiscal 2013 and 2012, Agile paid the Company $3.5 million for leasehold improvements incurred by the Company for its facilities to provide for adequate manufacturing space for this product once it is approved, which will be recognized as rental income in future years as the facility is used for production. In addition, for fiscal 2014 and 2013, Agile paid $1.0 and $0.6 million to the Company for idle facility charges, which are presented on the income statement as other revenues. Under the current agreements with Agile, the Company is not eligible for additional milestone payments.
	The term of the Company's contract with Agile continues until the Company has commercially produced an agreed-upon quantity of patches, currently projected to occur no earlier than five years following the commercial launch of AG200-15.
	Other Partner Arrangements
	In 2013, the Company entered into an arrangement for the development of two generic transdermal products. Under the arrangement, the partner and the Company will equally fund all costs of developing the products. The Company will be reimbursed for its share of all out of pocket costs and will be required to reimburse the partner for its share of all development, clinical and other costs up to and including regulatory filing. The Company may be reimbursed for the development costs that it incurs through the payment of certain development milestones up to a combined total of $4.7 million for both products, based on achieving certain stages of development. The Company received $0.5 million of these milestones upon signing the agreement and is amortizing these into revenue over the expected development period of the products.
	Upon regulatory approval, the Company will manufacture and sell the product to the partner at cost with no margin, but, provided that the Company has shared equally in all costs through regulatory approval, the Company will be paid a profit share equal to 50% of the net profits for each product.

Warrants

Warrants	12 Months Ended
	Sep. 30, 2014
Warrants
Warrants	11. Warrants
	The Company issued warrants to purchase shares of the Company's stock as part of several transactions from 2008 through 2013. The warrants have been recorded as either equity instruments or liability instruments based on the terms of the warrants.
	Preferred Stock Warrants
	As of September 30, 2013, the Company had issued warrants to purchase 1,739,992 shares of Series C preferred stock, with a weighted average exercise price of $0.90 per share, which comprised the only warrants to purchase preferred stock issued by the Company.
	All of the Series C preferred stock warrants were exercisable for a period of five years from issuance, except certain warrants to purchase 163,522 shares of Series C preferred stock which would have expired upon the closing of an IPO, unless exercised. The warrants were exercisable in cash or through a cashless exercise provision. Under the cashless exercise provision, the holder could, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the Series C preferred stock at the time of exercise of the warrant after deducting the aggregate exercise price. In the event that all outstanding shares of the Series C convertible preferred stock were converted into common stock, the warrants would be exercisable for the same number of shares of common stock.
	Of the warrants outstanding as of September 30, 2013, warrants to purchase 1,380,241 shares of Series C preferred stock contained antidilution protection. Accordingly, the Company evaluated these warrants as derivative instruments, and recorded the warrants as liabilities at fair value at the time of issuance, with the fair value then adjusted at each subsequent balance sheet date.
	The fair value of the outstanding convertible preferred stock warrants containing antidilution protection where remeasured quarterly using the Option Pricing Model in fiscal 2012 and the Probability-Weighted Expected Return Model thereafter. The Company used a number of assumptions to estimate the fair value including the likelihood of various scenarios, the expected volatility and the fair value of the underlying stock under each scenario. These assumptions were:
		Year ended
		September 30,
		2013
	Remaining contractual term (in years)	5.07 - 8.24
	Risk-free interest rate	1.39 - 2.02%
	Expected volatility	68 - 77%
	Expected dividend rate	0%
	The fair value of these warrants totaled $0.6 million as of September 30, 2013.
	On April 8, 2014, in connection with the closing of the IPO, all of the warrants to purchase 163,522 shares of Series C convertible preferred stock that were otherwise set to expire upon completion of the IPO were converted and net exercised into 1,191 shares of common stock, and the remainder of the outstanding warrants to purchase 1,216,719 shares of Series C convertible preferred stock , were converted into warrants to purchase common stock, representing 120,464 shares with a weighted average exercise price of $1.88 per share. In addition, the preferred stock warrant liability of $0.8 million was reclassified to stockholders' equity (deficit).
	Common Stock Warrants
	As of September 30, 2014 and 2013, warrants to purchase 128,582 and 1,294,613 shares of common stock were outstanding with a weighted average exercise price of $1.77 and $1.95 per share, including 120,464 shares of preferred stock warrants that were converted into warrants to purchase common stock in connection with the IPO in 2014. All of the common stock warrants are exercisable at any time up to five years from issuance. The fair value of these warrants was recorded in stockholders' equity (deficit) upon issuance.
	The Company issued a warrant for the purchase of 8,118 shares of common stock with a fair value totaling $15,000 in connection with a lease arrangement that closed in September 2013. The fair value of the warrant upon issuance was calculated using the Black-Scholes option-pricing valuation model with the following assumptions: common stock value of $3.03 per share, contractual term of 5 years, risk-free interest rate of 1.41%, expected volatility of 76%, and expected dividend yield of 0%. This warrant was outstanding as of September 30, 2014.
	On April 8, 2014, in connection with the closing of the IPO, warrants to purchase 1,286,495 shares of common stock were net exercised into 970,249 shares of common stock.

Convertible_Preferred_Stock_Re

Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)	12 Months Ended
	Sep. 30, 2014
Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)
Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)	12. Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)
	Convertible Preferred Stock
	Preferred stock totaling 5.0 million shares with a par value of $0.001 are authorized, but, as of September 30, 2014, no preferred stock was outstanding.
	Convertible preferred stock as of September 30, 2013, on an unconverted basis, consisted of the following (in thousands, except for share and per share data):
		Shares		Original		Shares Issued		Aggregate
		Authorized		Issue Price		and		Liquidation
						Outstanding		Amount
	Series A		1,114,100	$	0.220		1,114,066	$	490
	Series B		7,602,200		0.875		7,602,132		6,652
	Series C		57,000,000		0.917		27,318,702		50,119
	Balance as of September 30, 2013		65,716,300				36,034,900	$	57,261
	The Company recorded the convertible preferred stock at fair value on the dates of issuance. The Company classified the convertible preferred stock outside of stockholders' equity (deficit) because the shares contained liquidation features that were not solely within the Company's control.
	The rights, privileges, and preferences of Series A, Series B, and Series C convertible preferred stock were as follows:
	Voting Rights—The Series A, B, and C preferred stockholders had a right to the number of votes equal to the number of shares of common stock issuable upon conversion of the preferred stock, except as otherwise required by law. The Series C stockholders had protective provisions that required the Company to obtain their consent, by majority vote, before undertaking certain actions. In addition, all preferred stockholders, as a class, had protective provisions that required the Company to obtain their consent, by majority vote, before undertaking certain actions.
	Dividends—The Series A, B, and C preferred stockholders were entitled to receive noncumulative dividends, if and when declared by the board of directors prior and in preference to any dividend on common stock, at the rate of 8% of the original issue price.
	Conversion—Each share of preferred stock could have been converted, at the option of the holder, into such number of fully paid and nonassessable shares of common stock as was determined by dividing the original issue price for the relevant series of preferred stock by the then-applicable conversion price in effect at the time of conversion.
	Liquidation—In the event of a liquidation, dissolution, or winding up of the Company, the Series C preferred stockholders were entitled to a preference payment prior to any distribution of assets or surplus funds of the Company to the Series A and B preferred stockholders or to the common stockholders. The liquidation preference payments to the Series C preferred stockholders would have been two times the original issuance price of the Series C preferred stock, plus any accrued but unpaid dividends. Upon completion of the preference payment to the Series C preferred stockholders, the Series A and B preferred stockholders were entitled to share equally in preference payments until the Series B preferred stockholders received one times the original issuance price of the Series B preferred stock; thereafter, only the Series A preferred stockholders would have received preference payments until they had received a cumulative amount of two times the original issuance price of the Series A preferred stock. All of the foregoing preferred stock preferences would have been paid prior to any distribution of any assets or surplus funds of the Company to the common stockholders. The Company classified the convertible preferred stock outside of stockholders' equity (deficit) and recorded it at maximum liquidation value as the shares contained liquidation features that were not solely within its control.
	Participation—In the event of a liquidation, dissolution, or winding up of the Company, and only after all of the Series A, B, and C preferred stockholders had received all of their preference payments, any remaining assets or surplus funds of the Company would have been distributed ratably to the common stockholders and Series B preferred stockholders as if the Series B preferred stock had all been converted into common, but only to the extent that Series B stockholders were entitled to receive a maximum of one times the original issuance price of the Series B preferred stock from such distribution.
	Common Stock
	The Company was authorized to issue up to 150,000,000 and 115,000,000 shares of common stock as of September 30, 2014 and 2013 with a par value of $0.001 per share. The Company had reserved shares of common stock, on an as-if converted basis, for issuance as follows:
		As of September 30,
		2014		2013
	Issuances under stock option plans		2,089,586		1,781,846
	Issuances upon conversion of convertible preferred stock		—		3,567,811
	Issuances upon exercise of convertible preferred stock warrants		—		172,276
	Issuances upon exercise of common stock warrants		128,582		1,294,618
	Issuances under the 2014 employee stock purchase plan		310,000		—
			2,528,168		6,816,551
	Repurchases of Common Stock from Founders—In connection with the 2007 Series C financing, the Company, in accordance with specific stock repurchase agreements approved by the board of directors, purchased from the two founders an aggregate of 215,872 shares of common stock at a purchase price of $9.26 per share. The stock repurchase agreements also provided for the Company to repurchase an additional 215,872 shares of common stock from each of the two founders at a price of $9.26 per share. These agreements were amended in March 2008 to suspend the Company's obligation to repurchase these shares if, in the discretion of the Company's board of directors, any such repurchase would result in a material adverse effect on the Company's financial condition. As these shares were conditionally redeemable, they were classified outside of stockholders' equity (deficit).
	As of September 30, 2013, the Company had a remaining agreement to repurchase 132,073 from one founder and 215,872 from the other founder, but such repurchase was contingent on approval by the board of directors. In December 2013, the Company entered into a revised repurchase agreement pursuant to which the Company agreed to repurchase 1,077,809 shares of the Company's common stock from the founders, for an aggregate repurchase price of $5.2 million. On April 8, 2014, in connection with the closing of the IPO, the Company repurchased all 1,077,809 shares of common stock from the founders, thereby satisfying in full all of the Company's remaining obligations under the earlier repurchase agreements.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Sep. 30, 2014
Stock-Based Compensation
Stock-Based Compensation	13. Stock-Based Compensation
	Equity Incentive Plan
	As of September 30, 2014 and September 30, 2013, the Company had four and three equity incentive plans, respectively, all of which are sponsored by the Company, with the exception of the separate stock option plan of StrataGent, Inc., a corporation acquired by the Company on September 20, 2007 (the "StrataGent Plan"). The Company assumed all unexpired, unexercised options outstanding for those employees of StrataGent who remained Company employees after the merger. Each StrataGent option became exercisable into whole shares of Corium stock based on an agreed exchange ratio and per share exercise price such that the total value of the option grant did not change. The Company elected to make no further grants under the StrataGent Plan; however, its terms continue to govern all options issued under that plan. No additional shares available for grant were assumed by the Company, and any options that were returned to the pool subsequent to the merger were canceled and were not made available for future grants. This wholly-owned subsidiary was dissolved in 2008.
	On March 20, 2014, the Company's board of directors approved the adoption of the 2014 Equity Incentive Plan (the "2014 Plan"), which became effective in connection with the IPO. Under the 2014 Plan, the Company has reserved a total of 1.0 million shares of common stock plus the remaining unissued shares under the Company's 2012 Equity Incentive Plan (the "2012 Plan"), which had been adopted in November 2012 and was replaced by the 2014 Plan. The Company also sponsored the 2002 Stock Option Plan that expired in 2012. On January 1 of each year for the ten year term of the 2014 Plan, the number of shares of common stock issuable under the 2014 Plan can be increased by an amount equal to up to 4% of the number of shares of common stock and common stock equivalents outstanding as of the preceding December 31, or such lesser number agreed to by the board of directors.
	The exercise price of each option issued under each of the equity incentive plans is required to be no less than the fair value of the Company's capital stock, as determined by the board of directors on the date of the grant. The maximum term of the options is ten years and the vesting period is typically four years. The Corium Plan comprises the 2014 Plan, the 2012 Plan and the 2002 Stock Option Plan.
	Performance-Based Stock Option Grants—During the year ended September 30, 2013, the Company granted options to purchase 146,024 shares of common stock to certain executive officers and directors, which contained performance-based vesting criteria. These shares vest upon completion of certain milestone events which are specific to the Company's corporate goals. Stock-based compensation expense associated with these performance-based stock options is recognized if the performance condition is considered probable of achievement using management's best estimates. Following the closing of the IPO in April 2014, the Compensation Committee of the Company's board of directors determined that the performance-based criteria was met for options related to 137,510 shares of common stock and, accordingly, the Company has recorded stock-based compensation expense of $0.3 million for the year ended September 30, 2014 related to these performance-based stock options.
	A summary of activity under the Corium Plan during fiscal 2014, 2013 and 2012 is as follows:
		Shares			Stock			Weighted		Weighted		Aggregate
		Available			Options			Average		Average		Intrinsic Value
		for Grant			Outstanding			Exercise		Remaining		(In thousands)
								Price		Contractual
										Life (Years)
	Balance—October 1, 2011		175,811			813,900		$	3.43
	Forfeited / Cancelled		55,486			(55,486	)	$	6.67
	Balance—September 30, 2012		231,297			758,414		$	3.13		5.2
	Additional shares authorized		792,079			—			—
	Granted		(993,327	)		993,327		$	2.22
	Exercised		—			(4,504	)	$	2.32
	Forfeited / Cancelled		218,361			(218,361	)	$	5.93
	Balance—September 30, 2013		248,410			1,528,876		$	2.22		7.22	$	1,287
	Additional shares authorized		1,272,277			—			—
	Granted		(573,589	)		573,589		$	4.86
	Exercised		—			(14,650	)	$	2.32
	Forfeited / Cancelled		2,787			(2,787	)	$	3.3
	Balance—September 30, 2014		949,885			2,085,028		$	2.92		7.02	$	6,710
	Options exercisable—September 30, 2014					1,240,629		$	2.39		5.89	$	4,647
	Options vested and expected to vest—September 30, 2014					2,047,439		$	2.91		7	$	6,589
	All outstanding options under the Corium Plan as of September 30, 2014 have an exercise price between $2.12 and $8.18 per share.
	The weighted average grant date fair value of options granted was $8.03 and $1.31 for fiscal 2014 and 2013. The Company estimated the fair value of stock options granted during fiscal 2014 and 2013 using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of the employee stock options was estimated using the following assumptions:
		Year ended September 30,
		2014		2013
	Expected term (in years)	5.27 - 6.08		2.50 - 6.08
	Risk-free interest rate	1.61% - 2.25%		0.70% - 1.38%
	Expected volatility	63% - 74%		71% - 75%
	Expected dividend rate	0%		0%
	A summary of activity under the StrataGent Plan for fiscal 2014, 2013 and 2012 is as follows:
		Stock Options			Weighted Average			Weighted Average		Aggregate
		Outstanding			Exercise Price			Remaining		Intrinsic Value
								Contractual		(In thousands)
								Life (Years)
	Balance—October 1, 2011		97,276		$	0.2
	Exercised		(61,799	)	$	0.2
	Balance—September 30, 2012		35,477		$	0.2			1.82
	Exercised		(21,684	)	$	0.1
	Forfeited		(9,233	)	$	0.2
	Balance—September 30, 2013		4,560		$	0.71			3.13	$	11
	Balance—September 30, 2014		4,560		$	0.71			2.13	$	25
	Options exercisable—September 30, 2014		4,560		$	0.71			2.13	$	25
	Options vested and expected to vest—September 30, 2014		4,560		$	0.71			2.13	$	25
	All outstanding options under the StrataGent Plan have an exercise price between $0.18 and $0.88 per share. There were no options granted under the StrataGent Plan during fiscal 2014, 2013 or 2012.
	2014 Employee Stock Purchase Plan
	On March 20, 2014, the Company's board of directors approved the adoption of the 2014 Employee Stock Purchase Plan (the "2014 ESPP"), which became effective in connection with the IPO. Under the 2014 ESPP, the Company has reserved a total of 310,000 shares of common stock for issuance to employees. On January 1 of each year for the ten year term of the plan, the number of shares issuable under the 2014 ESPP can be increased by action of the board of directors by an amount equal to up to 1% of the number of shares of common stock and common stock equivalents outstanding as of the preceding December 31, or a lesser number agreed to by the board of directors. No more than 4.0 million shares may be issued over the ten year term of the 2014 ESPP without the consent of the Company's stockholders. No shares under the 2014 Plan had been issued as of September 30, 2014. Shares subject to purchase rights granted under the Company's 2014 ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the Company's 2014 ESPP. The 2014 ESPP is intended to qualify as an "employee stock purchase plan," under Section 423 of the Internal Revenue Code of 1986 with the purpose of providing employees with an opportunity to purchase the Company's common stock through accumulated payroll deductions. The 2014 ESPP provides for a two-year offering period with four, six-month purchase windows during each offering period. Employees are able to purchase shares of common stock at 85% of the lower of the fair market value of the Company's common stock on the first day of the offering period or on the last day of the six-month purchase window. For the year ended September 30, 2014, the Company recorded stock-based compensation expense of $253,000 related to the 2014 ESPP.
	The weighted average fair value of the shares expected to be purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following assumptions:
		Year Ended
		September 30, 2014
	Expected term (in years)	0.63 - 2.13
	Expected volatility	42 - 55%
	Risk-free interest rate	0.07 - 0.52%
	Expected dividend rate	0%
	Fair Value of Common Stock—The fair value of the shares of common stock is based on 85% of the Company's IPO price for the first offering period.
	Expected Term—The expected term is based on the term of the offering period under the 2014 ESPP and can be either six, twelve, eighteen or twenty four months.
	Expected Volatility—Because the Company has limited information on the volatility of its common stock due to a lack of significant trading history and limited historical data regarding the volatility of its common stock, the expected volatility used is based on the volatility of a group of comparable publicly traded companies. In evaluating comparability, the Company considered factors such as industry, stage of life cycle and size. The Company will continue to analyze the historical stock price volatility and term assumptions as more historical data for the Company's common stock becomes available.
	Risk-Free Interest Rate—The risk-free interest rate is based on the constant maturity yields of U.S. Treasury notes with remaining maturities similar to the expected term.
	Expected Dividend Rate—The Company has never paid any dividends, does not plan to pay dividends in the foreseeable future, and, therefore, uses an expected dividend rate of zero in the valuation model.
Stock-Based Compensation Expense
Employee stock-based compensation expense for fiscal 2014, 2013 and 2012 is classified in the statements of operations and comprehensive loss as follows (in thousands):
	Years ended
	September 30,
	2014			2013			2012
Cost of product revenues	$	188		$	35		$	—
Cost of contract research and development revenues		196			21			—
Research and development		151			39			—
General and administrative		1,094			235			66
Total stock-based compensation	$	1,629		$	330		$	66
As of September 30, 2014, there was a total of $4.1 million of unrecognized employee compensation cost, net of estimated forfeitures, related to non-vested stock option awards and the 2014 ESPP, which is expected to be recognized on a straight-line basis over a weighted-average period of approximately 3.1 years.

Product_Recall_Liability

Product Recall Liability	12 Months Ended
	Sep. 30, 2014
Product Recall Liability
Product Recall Liability	14. Product Recall Liability
	In fiscal 2008 and fiscal 2010, Actavis issued two voluntary recalls of certain lots and strengths of Fentanyl TDS manufactured by the Company and sold and distributed by Actavis in the United States. The Company and Actavis negotiated financial settlements for these two recalls, and the Company accrued amounts related to these settlements in fiscal 2009 and 2011. Such recall liabilities were subsequently reduced through various mechanisms per the terms of the settlement agreements.
	In October 2012, the Company reached a revised settlement related to the two recalls which provided for a total and combined remaining liability of $5.0 million as of September 30, 2012. The revised liability will be repaid through quarterly payments in arrears based on a percentage of the average of the total net revenues recorded by the Company related to Fentanyl TDS. These payments have been paid to Actavis starting in July 1, 2013 and will continue through April 1, 2017. To the extent that the revised settlement liability is not repaid as of April 1, 2017, the remaining liability, if any, will be converted into the most recent form of capital stock issued by the Company in connection with a financing, at the price per share of that financing. The revised liability does not accrue interest. As a result of the revised settlement, the Company recorded a gain on settlement of the recall liability of $0.6 million which is included in the statement of operations and comprehensive loss for the year ended September 30, 2012. During fiscal 2014 and 2013, the Company repaid $1.1 million and $0.2 million of this liability.
	The following table summarizes the changes to the product recall liability (in thousands):
		Year Ended September 30,
		2014			2013			2012
	Beginning balance	$	4,832		$	5,000		$	8,623
	Non-cash reductions in recall liability prior to settlement		—			—			(3,041	)
	Gain on settlement of recall liability		—			—			(582	)
	Payment of settlement liability		(1,122	)		(168	)		—
	Ending balance	$	3,710		$	4,832		$	5,000

Product_Liability

Product Liability	12 Months Ended
	Sep. 30, 2014
Product Liability
Product Liability	15. Product Liability
	As discussed in Note 9, there are other potential liabilities that the Company may incur relating to the products it manufactures, including potential product liability claims. For fiscal 2014, 2013 and 2012, the Company has provided a reserve for these claims taking into account the insurance coverage maintained for such claims, the nature and extent of such claims, and the Company's past success in defending and/or settling such claims. The Company does not expect a material financial impact to arise from such claims to date.
	The following table summarizes the changes to the product liability reserve (in thousands):
		Year Ended September 30,
		2014			2013			2012
	Beginning balance	$	90		$	720		$	500
	Settlement payments		—			(1,300	)		(307	)
	Expense (income)		(5	)		670			527
	Ending balance	$	85		$	90		$	720

Net_Loss_and_Net_Loss_per_Shar

Net Loss and Net Loss per Share Attributable to Common Stockholders	12 Months Ended
	Sep. 30, 2014
Net Loss and Net Loss per Share Attributable to Common Stockholders
Net Loss and Net Loss per Share Attributable to Common Stockholders	16. Net Loss and Net Loss per Share Attributable to Common Stockholders
	The following table sets forth the computation of the Company's basic and diluted net loss per share attributable to common stockholders during fiscal 2014, 2013 and 2012 (in thousands, except share and per share data):
		Year Ended September 30,
		2014			2013			2012
	Net loss attributable to common stockholders, basic and diluted	$	(9,912	)	$	(13,877	)	$	(5,443	)
	Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted		10,043,640			2,222,981			2,200,727
	Net loss per share attributable to common stockholders, basic and diluted	$	(0.99	)	$	(6.24	)	$	(2.47	)
	The following outstanding shares of common stock equivalents were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:
		Year Ended September 30,
		2014			2013			2012
	Convertible preferred stock		—			3,567,811			3,567,811
	Stock options to purchase common stock		2,089,586			1,781,844			1,025,188
	Shares authorized under the 2014 ESPP		310,000			—			—
	Common stock warrants		128,582			1,294,618			1,269,634
	Preferred stock warrants		—			172,276			172,276

Income_Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2014
Income Taxes
Income Taxes	17. Income Taxes
	The Company's effective tax rate differs from the statutory federal income tax rate, primarily as a result of the net operating loss carryforwards and research and development tax credit carryforwards.
	The Company operates in only one jurisdiction, the United States. The following table presents a reconciliation of the tax expense (benefit) computed at the statutory federal rate and the Company's tax expense (benefit) for the period presented (in thousands):
		Year Ended September 30,
		2014			2013			2012
	Income tax benefit—computed as 34% of pretax loss	$	(3,370	)	$	(4,717	)	$	(1,851	)
	Effect of nondeductible expenses		695			695			881
	State and local income tax expenses		1			1			(6	)
	Valuation allowance		2,403			4,270			876
	Effect of tax credits and other		(13	)		(50	)		(1	)
	State deferred taxes		285			(188	)		75
	Other		—			(10	)		19
	Total	$	1		$	1		$	(7	)
	The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities as of September 30, 2014 and 2013 are as follows (in thousands):
		As of September 30,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforward	$	26,279		$	21,491
	Depreciation		694			720
	Accrued expenses		1,686			1,782
	Research and development tax credit		1,982			1,970
	State deferred taxes		1,651			1,965
	Subordinated debt embedded derivative		—			2,505
	Other		1,508			801
	Gross deferred tax assets		33,800			31,234
	Valuation allowance		(33,518	)		(30,997	)
	Net deferred tax assets		282			237
	Deferred tax liabilities:
	Other		(282	)		(237	)
	Gross deferred tax liabilities		(282	)		(237	)
	Net deferred tax liabilities	$	—		$	—
	As of September 30, 2014, the Company had net operating loss carryforwards for federal and state income tax purposes of $77.3 million and $12.8 million. These net operating loss carryforwards will expire, if not utilized, beginning in 2026 and 2017 for federal and state income tax purposes, respectively.
	Realization of deferred tax assets is dependent on future taxable income, the existence and timing of which is uncertain. Based on the Company's history of losses, management has determined it cannot conclude that it is more likely than not that the deferred tax assets will be realized, and accordingly has placed a full valuation allowance on its net deferred tax assets. The valuation allowance increased by $2.5 million and $4.3 million in fiscal 2014 and 2013.
	As of September 30, 2014, the Company had research and development tax credit carryforwards of $2.0 million and $1.4 million available to reduce future taxable income, if any, for federal and California state income tax purposes. The federal tax credit carryforwards begin to expire in 2022. California credits have no expiration date.
	The Tax Reform Act of 1986 and similar California legislation impose substantial restrictions on the utilization of net operating losses and tax credits in the event of an ownership change of a corporation. Accordingly, the Company's ability to utilize net operating losses and research and development tax credit carryforwards may be significantly limited in the future as a result of such an ownership change.
	The Company did not have any material unrecognized tax benefits as of September 30, 2014 and 2013. It is difficult to predict the final timing and resolution of any particular uncertain tax position. Based on the Company's assessment, including experience and complex judgments about future events, the Company does not expect that changes in the amount of unrecognized tax benefits during the next 12 months will have a significant impact on the Company's financial position or results of operations. On January 1, 2009, the Company adopted the provisions of FASB's guidance for accounting for uncertain tax positions. The guidance prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. The cumulative effect of adopting this guidance did not result in an adjustment to accumulated deficit as of January 1, 2009. No liability related to uncertain tax positions is recorded in the financial statements.
	It is the Company's policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, as necessary. There was no interest expense or penalties related to unrecognized tax benefits recorded through September 30, 2014.
	The Company files income tax returns in the U.S. federal jurisdiction as well as in California, Michigan, and New Jersey. The tax years ending September 30, 2011 to September 30, 2013 remain open to examination by the jurisdictions in which the Company is subject to tax. Fiscal years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early years, which have been carried forward and may be audited in subsequent years when utilized.

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Sep. 30, 2014
Employee Benefit Plan
Employee Benefit Plan	18. Employee Benefit Plan
	The Company has a defined-contribution retirement plan that allows for discretionary contributions from the Company. Contributions totaled $93,000, $90,000 and $80,000 for fiscal 2014, 2013 and 2012.

Segment_and_EnterpriseWide_Inf

Segment and Enterprise-Wide Information	12 Months Ended
	Sep. 30, 2014
Segment and Enterprise-Wide Information
Segment and Enterprise-Wide Information	19. Segment and Enterprise-Wide Information
	The Company's chief operating decision maker is its chief executive officer. The chief executive officer reviews its operating results on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, or operating results for levels or components. Accordingly, the Company has a single reporting segment and operating unit structure.
	All of the Company's revenues are derived from partners located in the United States and all long-lived assets are located in the United States.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Sep. 30, 2014
Selected Quarterly Financial Data (Unaudited)
Selected Quarterly Financial Data (Unaudited)	20. Selected Quarterly Financial Data (Unaudited)
	Selected quarterly results from operations for the years ended September 30, 2014 and 2013 are as follows (in thousands, except per share amounts):
		Fiscal 2014 Quarter Ended
		December 31,			March 31,			June 30,			September 30,
		2013			2014			2014			2014
	Total revenue	$	10,468		$	10,717		$	10,183		$	11,072
	Operating expenses	$	11,530		$	11,511		$	13,580		$	15,869
	Net income (loss)	$	(2,098	)	$	3,534		$	(4,981	)	$	(6,367	)
	Basic net income (loss) per common share	$	(0.94	)	$	0.5		$	(0.28	)	$	(0.35	)
	Diluted net income (loss) per common share	$	(0.94	)	$	0.33			(0.28	)	$	(0.35	)
		Fiscal 2013 Quarter Ended
		December 31,			March 31,			June 30,			September 30,
		2012			2013			2013			2013
	Total revenue	$	12,624		$	12,536		$	12,566		$	12,544
	Operating expenses	$	12,287		$	12,614		$	11,795		$	12,373
	Net loss	$	(1,433	)	$	(1,999	)	$	(9,163	)	$	(1,282	)
	Basic and diluted net loss per common share	$	(0.65	)	$	(0.90	)	$	(4.12	)	$	(0.58	)

Subsequent_Events

Subsequent Events	12 Months Ended
	Sep. 30, 2014
Subsequent Events
Subsequent Events	21. Subsequent Events
	In November 2014, the Company amended and restated its existing term loan agreement (see Note 8). Among other things, this amendment increased the loan principal amount to $45.0 million (excluding PIK notes), and extended the maturity date to June 30, 2019. Interest only payments are due quarterly through June 30, 2018, and principal and interest payments are due in four quarterly installments beginning September 30, 2018. Interest will continue to accrue on both the loan and PIK notes at a rate of 15% per year, of which up to 3.5% can be converted each quarter into PIK notes on or prior to September 30, 2018.

Organization_Description_of_Bu1

Organization, Description of Business, and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2014
Organization, Description of Business, and Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation
	The Company's financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America.
Reverse Stock Split	Reverse Stock Split
	On March 20, 2014, the Company effected a 1-for-10.1 reverse stock split of the Company's outstanding common stock resulting in a reduction of the Company's total common stock issued and outstanding from 19,032,056 shares to 1,884,362 shares. The reverse stock split affected all stockholders of the Company's common stock uniformly, and did not materially affect any stockholder's percentage of ownership interest. The par value of the Company's common stock remained unchanged at $0.001 per share and the number of authorized shares of common stock remained the same after the reverse stock split.
	In connection with this reverse stock split, the number of shares of common stock reserved for issuance under the Company's equity incentive, stock option and employee stock purchase plans, as well as the shares of common stock underlying outstanding stock options, restricted stock units and warrants, were also proportionately reduced while the exercise prices of such stock options and warrants were proportionately increased. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis.
Initial Public Offering	Initial Public Offering
	On April 2, 2014, the Company's registration statements on Form S-1 (File No. 333-194279 and File No. 333-195002) relating to the Initial Public Offering (the "IPO") of its common stock were declared effective by the SEC. The IPO closed on April 8, 2014 at which time the Company sold 6,500,000 shares of its common stock at a price of $8.00 per share. The Company also granted the underwriters a 30-day option to purchase up to 975,000 additional shares of common stock at the IPO price. The underwriters exercised this option to purchase 374,997 shares on May 2, 2014. The Company received cash proceeds of $48.5 million from the IPO, including proceeds from the partial exercise of the underwriters' option, net of underwriting discounts, commissions and issuance costs paid by the Company, which totaled $2.7 million.
	On April 8, 2014, immediately prior to the closing of the IPO, all outstanding shares of convertible preferred stock converted into 3,567,807 shares of common stock, and the related carrying value of $57.3 million was reclassified to common stock and additional paid-in capital. In addition, certain warrants to purchase convertible preferred stock and common stock were also converted and net exercised into 971,440 shares of common stock. Upon the closing of the IPO, Corium also repurchased 1,077,809 shares of common stock from its founders, for an aggregate purchase price of $5.2 million.
	Following the filing of the Restated Certificate of Incorporation of the Company on April 8, 2014, the number of shares of capital stock the Company is authorized to issue is 155,000,000 shares, of which 150,000,000 shares may be common stock and 5,000,000 shares may be preferred stock. Both the common stock and preferred stock have a par value of $0.001 per share.
Use of Estimates	Use of Estimates
	Estimates and assumptions are required to be used by management in the preparation of financial statements in conformity with accounting principles generally accepted in the United States of America that affect the reported amounts of assets, liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of operating revenues and operating expenses during the reporting period. Those estimates and assumptions affect revenue recognition and deferred revenues, impairment of long-lived assets, determination of fair value of stock-based awards and other debt and equity related instruments, and accounting for income taxes. As future events and their effects cannot be determined with precision, actual results could differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents with a single domestic financial institution that is well capitalized. The Company provides credit, in the normal course of business, to its partners and performs credit evaluations of such partners.
	Four partners accounted for 95%, 99% and 94% of the Company's revenues for fiscal 2014, 2013 and 2012. These same partners accounted for 95% and 100% of accounts receivable as of September 30, 2014 and 2013.
Revenue Recognition	Revenue Recognition
	The Company generates revenues from agreements for the development and commercialization of its products. The terms of the agreements may include nonrefundable upfront payments, partial or complete reimbursement of research and development costs, milestone payments, product sales, and profit sharing and royalties on product sales made by the partners. The Company recognizes revenues when the following criteria are met: persuasive evidence of a sales or service arrangement exists; delivery has occurred; the price is fixed or determinable; and collectability is reasonably assured.
	Revenue related to multiple element arrangements are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. This determination is generally based on whether any deliverable has stand-alone value to the partner. This analysis also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting. The selling price used for each unit of accounting is based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific nor third-party evidence is available. Typically, the Company has not granted licenses to partners at the beginning of its arrangements and, thus, there are no delivered items separate from the research and development services provided. As such, upfront payments are recorded as deferred revenues in the balance sheet and are recognized as contract research and development revenues over the estimated period of performance that is consistent with the terms of the research and development obligations contained in the agreement. The Company periodically reviews the estimated period of performance based on the progress made under each arrangement.
	Amounts related to research and development funding are generally recognized as the related services or activities are performed in accordance with the contract terms. To the extent that agreements specify services are to be performed on a cost-plus basis, revenues are recognized as services are rendered. Such work is generally billed on a monthly basis for time incurred at specified rates in the agreements. To the extent that agreements specify services to be performed on a fixed-price basis, revenues are recognized consistent with the pattern of the work performed. Generally, all of the agreements provide for reimbursement of third-party expenses, and such reimbursable expenses are billed as revenues as incurred.
	The arrangements may include contractual milestones, which relate to the achievement of pre-specified research, development, regulatory and commercialization events. The milestone events contained in the Company's arrangements coincide with the progression of the Company's product candidates from research and development, to regulatory approval and through to commercialization. The process of successfully developing a new product, having it approved from a regulatory perspective and ultimately sold for a profit is highly uncertain. As such, the milestone payments that the Company may earn from its partners involve a significant degree of risk to achieve. Research and development milestones in the Company's strategic alliances may include the following types of events: completion of pre-clinical research and development work, completion of certain development events and initiation of clinical trials. Regulatory milestones may include the following types of events: filing of regulatory applications with the Food and Drug Administration and approval of the regulatory applications by the Food and Drug Administration. Commercialization milestones may include product launch. The Company recognizes milestone payments in the period in which the performance obligation underlying the milestone is achieved.
	Upon commercialization, revenues are generated from product sales, royalties and profit sharing. Product sales are generally recognized as products are shipped and title and risk of loss pass to the partner. Royalties and profit sharing are generally recognized when the Company's partners sell the product to their customers and are based on a percentage of the Company's partners' net sales or net profits for products subject to our agreements. Product sales and royalty income are presented collectively as product revenues. Royalties and profit sharing totaled $6.7 million, $7.8 million and $6.4 million for fiscal 2014, 2013 and 2012.
	Other revenues consists of income derived from the Company's arrangements with its partners, whereby a portion of the revenues received under these agreements relates to rental income from embedded leases associated with manufacturing equipment and facilities specific to these relationships, as well as revenues associated with licenses granted to a third party for intellectual property related to a discontinued product.
Research and Development	Research and Development
	Research and development expenses primarily comprise salaries and benefits associated with research and development personnel, overhead and facility costs, pre-clinical and non-clinical development costs, clinical trial, and related clinical manufacturing costs, contract services, and other outside costs. Research and development costs, including costs to be subsequently reimbursed under development contracts, are charged to expense when incurred.
Advertising Costs	Advertising Costs
	The Company's advertising expenses were immaterial for fiscal 2014, 2013 and 2012.
Stock-Based Compensation	Stock-Based Compensation
	The Company accounts for stock-based compensation for all share-based awards made to employees and directors, including employee stock options and employee stock purchases related to the employee stock purchase plan, by measuring the cost of awards of equity instruments based on the grant-date fair value of the award. The Company determines the fair value of such awards using the Black-Scholes option-pricing model (the "Black-Scholes model"), which incorporates certain assumptions as follows:
	Expected Term—The expected term represents the period that the stock-based awards are expected to be outstanding before exercise or cancellation. As the Company's historical share exercise experience did not provide a reasonable basis upon which to estimate expected term because of a lack of sufficient data points, the Company estimated the expected term by using the simplified method.
	Risk-Free Interest Rate—The risk-free interest rate is based on the implied constant maturity yield currently available on U.S. Treasury issues with a maturity consistent with the expected term.
	Expected Volatility—Because the Company has limited information on the volatility of its common stock due to a lack of significant trading history and limited historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of comparable publicly traded companies. In evaluating comparability, the Company considered factors such as industry, stage of life cycle and size. The Company will continue to analyze the historical stock price volatility and term assumptions as more historical data for the Company's common stock becomes available.
	Expected Dividend—The Company does not anticipate declaring dividends in the foreseeable future.
	The Company recognizes compensation expense for the portion of share-based awards that are expected to vest. Therefore, the Company applied estimated forfeiture rates that were derived from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.
Income Taxes	Income Taxes
	The Company accounts for income taxes based on the liability method. Under the liability method, deferred tax assets and deferred tax liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and deferred tax liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and deferred tax liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will not be realized.
Comprehensive Income (Loss)	Comprehensive Income (Loss)
	During fiscal 2014, 2013 and 2012, the Company did not recognize any other comprehensive income (loss) and, therefore, the net income (loss) and comprehensive income (loss) was the same for all periods presented.
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders
	The Company calculates its basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for companies with participating securities. The Company's basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of the diluted calculation, convertible preferred stock, options to purchase common stock and common stock warrants are considered common stock equivalents but are excluded from the calculation of diluted net loss per share attributable to common stockholders if their effect is antidilutive.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company generally invests funds that are in excess of current needs in high-credit-quality instruments, such as obligations of U.S. government agencies and money market funds.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are stated at invoiced amounts. An allowance for doubtful accounts is established as needed based on a specific assessment of all invoices that remain unpaid following normal partner payment periods. All amounts deemed to be uncollectible are charged against the allowance for doubtful accounts in the period that the determination is made. The allowance for doubtful accounts was $0 as of September 30, 2014 and 2013.
Inventories	Inventories
	Inventories are stated at the lower of cost, on a first-in, first-out basis, or market. The Company records an allowance for excess and obsolete inventory based on anticipated obsolescence, usage, and historical write-offs.
Property and Equipment	Property and Equipment
	Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Equipment is depreciated over its useful life, ranging from 3 to 8 years using the straight-line method. Leasehold improvements are depreciated or amortized over the shorter of the lease term or their useful lives ranging from 3 to 15 years using the straight-line method. Expenditures for maintenance and repairs are charged to expense as incurred.
Capital Leases	Capital Leases
	The Company leases several pieces of equipment under capital lease arrangements. During the year ended September 30, 2011, the Company completed two transactions, whereby existing manufacturing equipment was sold to and leased back from the lessor. Under these transactions, a gain on the sale was deferred and is being amortized over the life of the lease. Equipment leased under capital leases is amortized over the life of the lease term using the straight-line method.
Intangible Assets	Intangible Assets
	Intangible assets consist primarily of the cost of acquired patents and legal costs associated with patent development and contract acquisition costs. These costs are capitalized and amortized on a straight-line basis over the lesser of the estimated economic lives of the patents or the underlying contracts and the remaining legal lives of the patents, which approximates the consumption over the estimated useful lives of the assets, once a patent is granted. The Company periodically reevaluates the original assumptions and rationale utilized in the establishment of the carrying value and estimated lives of these assets.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the assets and their eventual disposition. Measurement of an impairment loss for long-lived assets that management expects to hold and use is based on the fair value of the asset. No impairment was recorded for fiscal 2014, 2013 or 2012.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Assets and liabilities recorded at fair value in the financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows:
	Level I—Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
	Level II—Inputs (other than quoted prices included in Level I) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument's anticipated life.
	Level III—Unobservable inputs that are supported by little or no market activity, but are significant to the fair value of the assets or liabilities. They reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.
Convertible Preferred Stock Warrants	Convertible Preferred Stock Warrants
	Prior to their conversion into common stock on April 8, 2014 in connection with the Company's IPO, the Company accounted for certain warrants to purchase shares of convertible preferred stock as liabilities at fair value, as it had determined that some of these warrants were derivative instruments because they contained antidilution provisions that protected the holders from certain equity issuances at a price below the original issue price of the underlying security. The Company remeasured these warrants to fair value at each balance sheet date, and recognized any change in the fair value as a change in the warrant liability in its statements of operations and comprehensive loss. The Company estimated the fair value of these warrants at the respective balance sheet dates using the Option Pricing Model, or OPM, in fiscal 2012 and  the Probability-Weighted Expected Return Model, or PWERM, thereafter. The Company used a number of assumptions to estimate the fair value, including the likelihood of various scenarios, the expected volatility, and the fair value of the underlying stock under each scenario.
Subordinated Note Embedded Derivative Liability	Subordinated Note Embedded Derivative Liability
	Prior to its conversion into common stock on April 8, 2014 in connection with the Company's IPO, the Company had an outstanding subordinated note that the Company had determined contained an embedded derivative instrument related to redemption and conversion features of the note. These features required bifurcation and separate accounting, and were accounted for as a liability. The embedded derivative liability was remeasured to fair value at each balance sheet date, with the corresponding gain or loss from the adjustment recorded in the statements of operations and comprehensive loss. The fair value of the embedded derivative was measured with the PWERM valuation methodology. Under this methodology, fair value is primarily driven by the assessment of the probability and timing of scenarios that could result in the redemption of the note prior to the note's maturity, which would trigger the payment of the additional amount equal to the outstanding principal of the subordinated note.
Recent Account Pronouncements	Recent Account Pronouncements
	In February 2013, the FASB issued guidance which addresses the presentation of amounts reclassified from accumulated other comprehensive income. This guidance does not change current financial reporting requirements. Instead, an entity is required to cross-reference to other required disclosures that provide additional detail about amounts reclassified out of accumulated other comprehensive income. In addition, the guidance requires an entity to present significant amounts reclassified out of accumulated other comprehensive income by line item of net income if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. Adoption of this standard is required for periods beginning after December 15, 2013. This new guidance impacts how the Company reports comprehensive income only, and had no effect on the Company's results of operations, financial position or liquidity during fiscal 2014 and 2013.
	In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, "Revenue from Contracts with Customers", Topic 606. This ASU affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The guidance in this ASU supersedes the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to illustrate the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance also includes a set of disclosure requirements that will provide users of financial statements with comprehensive information about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a reporting organization's contracts with customers. This ASU is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 15, 2016 for public companies. The Company is evaluating the effect, if any, on the Company's financial position and results of operations.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2014
Fair Value Measurements
Schedule of the Company's financial instruments that are measured at fair value on a recurring basis by level within the fair value hierarchy	The Company's financial instruments that are measured at fair value on a recurring basis as of September 30, 2014 and 2013, by level within the fair value hierarchy, are as follows (in thousands):
		As of September 30, 2014
		Level I			Level II		Level III			Total
	Financial Assets:
	Money market funds	$	36,019		$	—	$	—		$	36,019
	Total financial assets	$	36,019		$	—	$	—		$	36,019
		As of September 30, 2013
		Level I			Level II		Level III			Total
	Financial Assets:
	Money market funds	$	13,342		$	—	$	—		$	13,342
	Total financial assets	$	13,342		$	—	$	—		$	13,342
	Financial Liabilities:
	Preferred stock warrant liability	$	—		$	—	$	560		$	560
	Subordinated note embedded derivative liability		—			—		7,367			7,367
	Total financial liabilities	$	—		$	—	$	7,927		$	7,927
Summary of the changes in the fair value of the Company's Level III financial liabilities, which are measured on a recurring basis	The following table sets forth a summary of the changes in the fair value of the Company's Level III financial liabilities, which are measured on a recurring basis (in thousands):
		Year Ended
		September 30,
		2014			2013
	Beginning balance	$	7,927		$	546
	Change in fair value of preferred stock warrants		274			14
	Change in fair value of subordinated note embedded derivative liability		(7,367	)		7,367
	Extinguishment of preferred stock warrant liability		(834	)		—
	Ending balance	$	—		$	7,927
Schedule of differences between carrying values and estimated fair value of financial instruments	The following financial instruments have carrying values which differ from their fair value as estimated by the Company based on market quotes for instruments with similar terms and remaining maturities (Level III valuation technique) (in thousands):
		As of September 30, 2014
		Carrying			Fair Value		Difference
		Value
	Long-term debt	$	38,262		$	40,357	$	2,095
	Total	$	38,262		$	40,357	$	2,095
		As of September 30, 2013
		Carrying			Fair Value		Difference
		Value
	Long-term debt	$	37,413		$	37,413	$	—
	Convertible notes		9,399			14,316		4,917
	Subordinated note		13,000			9,508		(3,492	)
	Total	$	59,812		$	61,237	$	1,425

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Sep. 30, 2014
Inventories
Schedule of Inventories	Inventories consist of the following (in thousands):
		As of
		September 30,
		2014			2013
	Raw materials	$	1,268		$	2,410
	Work in process		898			1,546
	Finished goods		632			667
	Total inventories, cost		2,798			4,623
	Less inventory reserves		(206	)		(115	)
	Total inventories, net	$	2,592		$	4,508

Property_and_equipment_Tables

Property and equipment (Tables)	12 Months Ended
	Sep. 30, 2014
Property and equipment
Schedule of property and equipment	Property and equipment consist of the following (in thousands):
		As of September 30,
		2014			2013
	Machinery and equipment	$	12,242		$	11,145
	Manufacturing equipment acquired under capital leases		2,341			1,825
	Transportation equipment		25			25
	Furniture and fixtures		995			928
	Computer equipment and software		535			401
	Leasehold improvements		3,658			3,145
	Land		210			210
	Construction in progress		6,849			8,843
	Total property and equipment, gross		26,855			26,522
	Accumulated depreciation and amortization		(14,197	)		(13,900	)
	Total property and equipment, net	$	12,658		$	12,622

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Sep. 30, 2014
Intangible Assets
Schedule of intangible assets and related accumulated amortization	Intangible assets and related accumulated amortization consist of the following (in thousands):
		As of September 30,
		2014			2013
	Cost:
	Patents and trademarks	$	10,269		$	9,686
	Contract acquisition costs		1,672			1,677
	Total carrying value		11,941			11,363
	Accumulated amortization:
	Patents and trademarks		(3,756	)		(3,237	)
	Contract acquisition costs		(1,502	)		(1,479	)
	Total accumulated amortization		(5,258	)		(4,716	)
	Total intangible assets, net	$	6,683		$	6,647
Patents and trademarks
Intangible assets
Schedule of estimated remaining annual amortization expenses	The estimated remaining annual amortization expenses for issued patents and trademarks as of September 30, 2014 are as follows (in thousands):
	Year Ending September 30:	Amounts
	2015	$	584
	2016		584
	2017		584
	2018		584
	2019		584
	Thereafter		1,480
	Total	$	4,400
Contract acquisition cost
Intangible assets
Schedule of estimated remaining annual amortization expenses	The estimated remaining annual amortization expense for contract acquisition cost as of September 30, 2014 are as follows (in thousands):
	Year Ending September 30:	Amounts
	2015	$	29
	2016		29
	2017		29
	2018		29
	2019		29
	Thereafter		25
	Total	$	170

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Sep. 30, 2014
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consist of the following (in thousands):
		September 30,
		2014		2013
	Vacation	$	1,747	$	1,680
	Bonus		1,235		900
	Warranty liability		284		—
	Employee stock purchase plan liability		305		—
	Legal and professional fees		5		339
	Other		432		455
	Total accrued liabilities	$	4,008	$	3,374

Debt_Tables

Debt (Tables)	12 Months Ended
	Sep. 30, 2014
Debt
Schedule of the entity's outstanding debt	The Company's outstanding debt was as follows (in thousands):
		As of September 30,
		2014		2013
	Bank line of credit	$	—	$	3,873
	Long-term debt		38,262		37,413
	Convertible notes		—		9,399
	Subordinated note		—		13,000
	Total		38,262		63,685
	Less current portion, consisting of bank line of credit and long-term debt		107		4,330
	Long-term portion	$	38,155	$	59,355
Schedule of long-term debt	Long-term debt was as follows (in thousands):
		As of September 30,
		2014		2013
	Term loan agreement expiring June 30, 2017. See terms of the agreement below.
	Less discount of $76 and $103 as of September 30, 2014 and 2013	$	37,625	$	36,293
	Notes payable to lessor for tenant improvements. The note calls for monthly payments of principal and interest of $3 at an interest rate of 7% and is due April 2015		96		124
	Notes payable to lessor for tenant improvements. The note calls for monthly payments of principal and interest of $6 at an interest rate of 7% and is due November 2024		541		575
	Notes payable to finance Company insurance premiums. The note calls for monthly payments of principal and interest of $71 at an interest rate of 2.192% and was due March 2014		—		421
	Total		38,262		37,413
	Less current portion		107		457
	Long-term portion	$	38,155	$	36,956
Schedule of minimum principal payments on the entity's outstanding debt	Minimum principal payments on the Company's outstanding long-term debt, as of September 30, 2014 were as follows (in thousands):
	Year Ending September 30:	Amounts
	2015	$	107
	2016		9,439
	2017		28,296
	2018		46
	2019		49
	Thereafter		325
	Total	$	38,262

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 30, 2014
Commitments and Contingencies
Schedule of future minimum lease payments under capital leases, together with the present value of the net minimum lease payments	Future minimum lease payments under capital leases, together with the present value of the net minimum lease payments as of September 30, 2014, are as follows (in thousands):
	Year Ending September 30,	Amounts
	2015	$	897
	2016		877
	2017		73
	Total minimum lease payments		1,847
	Less amount representing estimated executory costs (such as taxes)		—
	Net minimum lease payments		1,847
	Less amount representing interest		(185	)
	Present value of net minimum lease payments		1,662
	Less discount related to warrants		(11	)
	Capital lease liability		1,651
	Less current portion		(760	)
	Long-term portion	$	891
Schedule of future minimum lease payments under operating leases that have initial or remaining lease terms in excess of one year	Future minimum lease payments under operating leases that had initial or remaining lease terms in excess of one year from September 30, 2014 were as follows (in thousands):
	Years Ending September 30,	Amounts
	2015	$	1,284
	2016		735
	2017		603
	2018		611
	2019		623
	Thereafter		3,653
	Total	$	7,509

Collaboration_and_Partner_Arra1

Collaboration and Partner Arrangements (Tables)	12 Months Ended
	Sep. 30, 2014
Collaboration and Partner Arrangements
Schedule of revenues from the entity's collaboration and partner agreements	The Company has recognized the following revenues from its collaboration and partner agreements during fiscal 2014, 2013, and 2012 (in thousands):
		Years ended September 30,
		2014		2013		2012
	P&G	$	11,719	$	11,781	$	7,880
	Teva		13,550		16,683		11,350
	Actavis/Par		12,971		16,551		18,139
	Agile		1,976		4,904		3,014
	Other		2,224		351		2,477
	Total revenues	$	42,440	$	50,270	$	42,860

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Sep. 30, 2014
Warrants
Schedule of assumptions used to estimate the fair value of outstanding warrants
		Year ended
		September 30,
		2013
	Remaining contractual term (in years)	5.07 - 8.24
	Risk-free interest rate	1.39 - 2.02%
	Expected volatility	68 - 77%
	Expected dividend rate	0%

Convertible_Preferred_Stock_Re1

Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Sep. 30, 2014
Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit)
Schedule of convertible preferred stock on an unconverted basis	Convertible preferred stock as of September 30, 2013, on an unconverted basis, consisted of the following (in thousands, except for share and per share data):
		Shares		Original		Shares Issued		Aggregate
		Authorized		Issue Price		and		Liquidation
						Outstanding		Amount
	Series A		1,114,100	$	0.220		1,114,066	$	490
	Series B		7,602,200		0.875		7,602,132		6,652
	Series C		57,000,000		0.917		27,318,702		50,119
	Balance as of September 30, 2013		65,716,300				36,034,900	$	57,261
Schedule of reserved shares of common stock, on an as-if converted basis, for issuance
		As of September 30,
		2014		2013
	Issuances under stock option plans		2,089,586		1,781,846
	Issuances upon conversion of convertible preferred stock		—		3,567,811
	Issuances upon exercise of convertible preferred stock warrants		—		172,276
	Issuances upon exercise of common stock warrants		128,582		1,294,618
	Issuances under the 2014 employee stock purchase plan		310,000		—
			2,528,168		6,816,551

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2014
Stock-based compensation
Schedule of employee stock-based compensation expense classified in the statements of operations and comprehensive loss	Employee stock-based compensation expense for fiscal 2014, 2013 and 2012 is classified in the statements of operations and comprehensive loss as follows (in thousands):
		Years ended
		September 30,
		2014			2013			2012
	Cost of product revenues	$	188		$	35		$	—
	Cost of contract research and development revenues		196			21			—
	Research and development		151			39			—
	General and administrative		1,094			235			66
	Total stock-based compensation	$	1,629		$	330		$	66
Corium Plan
Stock-based compensation
Summary of activity under the Plan
		Shares			Stock			Weighted		Weighted		Aggregate
		Available			Options			Average		Average		Intrinsic Value
		for Grant			Outstanding			Exercise		Remaining		(In thousands)
								Price		Contractual
										Life (Years)
	Balance—October 1, 2011		175,811			813,900		$	3.43
	Forfeited / Cancelled		55,486			(55,486	)	$	6.67
	Balance—September 30, 2012		231,297			758,414		$	3.13		5.2
	Additional shares authorized		792,079			—			—
	Granted		(993,327	)		993,327		$	2.22
	Exercised		—			(4,504	)	$	2.32
	Forfeited / Cancelled		218,361			(218,361	)	$	5.93
	Balance—September 30, 2013		248,410			1,528,876		$	2.22		7.22	$	1,287
	Additional shares authorized		1,272,277			—			—
	Granted		(573,589	)		573,589		$	4.86
	Exercised		—			(14,650	)	$	2.32
	Forfeited / Cancelled		2,787			(2,787	)	$	3.3
	Balance—September 30, 2014		949,885			2,085,028		$	2.92		7.02	$	6,710
	Options exercisable—September 30, 2014					1,240,629		$	2.39		5.89	$	4,647
	Options vested and expected to vest—September 30, 2014					2,047,439		$	2.91		7	$	6,589
Schedule of valuation assumptions used
		Year ended September 30,
		2014		2013
	Expected term (in years)	5.27 - 6.08		2.50 - 6.08
	Risk-free interest rate	1.61% - 2.25%		0.70% - 1.38%
	Expected volatility	63% - 74%		71% - 75%
	Expected dividend rate	0%		0%
StrataGent Plan
Stock-based compensation
Summary of activity under the Plan
		Stock Options			Weighted Average			Weighted Average		Aggregate
		Outstanding			Exercise Price			Remaining		Intrinsic Value
								Contractual		(In thousands)
								Life (Years)
	Balance—October 1, 2011		97,276		$	0.2
	Exercised		(61,799	)	$	0.2
	Balance—September 30, 2012		35,477		$	0.2			1.82
	Exercised		(21,684	)	$	0.1
	Forfeited		(9,233	)	$	0.2
	Balance—September 30, 2013		4,560		$	0.71			3.13	$	11
	Balance—September 30, 2014		4,560		$	0.71			2.13	$	25
	Options exercisable—September 30, 2014		4,560		$	0.71			2.13	$	25
	Options vested and expected to vest—September 30, 2014		4,560		$	0.71			2.13	$	25
2014 Employee Stock Purchase Plan
Stock-based compensation
Schedule of valuation assumptions used
		Year Ended
		September 30, 2014
	Expected term (in years)	0.63 - 2.13
	Expected volatility	42 - 55%
	Risk-free interest rate	0.07 - 0.52%
	Expected dividend rate	0%

Product_Recall_Liability_Table

Product Recall Liability (Tables)	12 Months Ended
	Sep. 30, 2014
Product Recall Liability
Summary of changes to the product recall liability	The following table summarizes the changes to the product recall liability (in thousands):
		Year Ended September 30,
		2014			2013			2012
	Beginning balance	$	4,832		$	5,000		$	8,623
	Non-cash reductions in recall liability prior to settlement		—			—			(3,041	)
	Gain on settlement of recall liability		—			—			(582	)
	Payment of settlement liability		(1,122	)		(168	)		—
	Ending balance	$	3,710		$	4,832		$	5,000

Product_Liability_Tables

Product Liability (Tables)	12 Months Ended
	Sep. 30, 2014
Product Liability
Summary of the changes to the product liability reserve	The following table summarizes the changes to the product liability reserve (in thousands):
		Year Ended September 30,
		2014			2013			2012
	Beginning balance	$	90		$	720		$	500
	Settlement payments		—			(1,300	)		(307	)
	Expense (income)		(5	)		670			527
	Ending balance	$	85		$	90		$	720

Net_Loss_and_Net_Loss_per_Shar1

Net Loss and Net Loss per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Sep. 30, 2014
Net Loss and Net Loss per Share Attributable to Common Stockholders
Schedule of computation of the Company's basic and diluted net loss per share attributable to common stockholders	The following table sets forth the computation of the Company's basic and diluted net loss per share attributable to common stockholders during fiscal 2014, 2013 and 2012 (in thousands, except share and per share data):
		Year Ended September 30,
		2014			2013			2012
	Net loss attributable to common stockholders, basic and diluted	$	(9,912	)	$	(13,877	)	$	(5,443	)
	Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted		10,043,640			2,222,981			2,200,727
	Net loss per share attributable to common stockholders, basic and diluted	$	(0.99	)	$	(6.24	)	$	(2.47	)
Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders
		Year Ended September 30,
		2014			2013			2012
	Convertible preferred stock		—			3,567,811			3,567,811
	Stock options to purchase common stock		2,089,586			1,781,844			1,025,188
	Shares authorized under the 2014 ESPP		310,000			—			—
	Common stock warrants		128,582			1,294,618			1,269,634
	Preferred stock warrants		—			172,276			172,276

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2014
Income Taxes
Schedule of reconciliation of the tax expense (benefit) computed at the statutory federal rate and the Company's tax expense (benefit)	The Company operates in only one jurisdiction, the United States. The following table presents a reconciliation of the tax expense (benefit) computed at the statutory federal rate and the Company's tax expense (benefit) for the period presented (in thousands):
		Year Ended September 30,
		2014			2013			2012
	Income tax benefit—computed as 34% of pretax loss	$	(3,370	)	$	(4,717	)	$	(1,851	)
	Effect of nondeductible expenses		695			695			881
	State and local income tax expenses		1			1			(6	)
	Valuation allowance		2,403			4,270			876
	Effect of tax credits and other		(13	)		(50	)		(1	)
	State deferred taxes		285			(188	)		75
	Other		—			(10	)		19
	Total	$	1		$	1		$	(7	)
Schedule of tax effects of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities	The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities as of September 30, 2014 and 2013 are as follows (in thousands):
		As of September 30,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforward	$	26,279		$	21,491
	Depreciation		694			720
	Accrued expenses		1,686			1,782
	Research and development tax credit		1,982			1,970
	State deferred taxes		1,651			1,965
	Subordinated debt embedded derivative		—			2,505
	Other		1,508			801
	Gross deferred tax assets		33,800			31,234
	Valuation allowance		(33,518	)		(30,997	)
	Net deferred tax assets		282			237
	Deferred tax liabilities:
	Other		(282	)		(237	)
	Gross deferred tax liabilities		(282	)		(237	)
	Net deferred tax liabilities	$	—		$	—

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Sep. 30, 2014
Selected Quarterly Financial Data (Unaudited)
Schedule of selected quarterly results from operations	Selected quarterly results from operations for the years ended September 30, 2014 and 2013 are as follows (in thousands, except per share amounts):
		Fiscal 2014 Quarter Ended
		December 31,			March 31,			June 30,			September 30,
		2013			2014			2014			2014
	Total revenue	$	10,468		$	10,717		$	10,183		$	11,072
	Operating expenses	$	11,530		$	11,511		$	13,580		$	15,869
	Net income (loss)	$	(2,098	)	$	3,534		$	(4,981	)	$	(6,367	)
	Basic net income (loss) per common share	$	(0.94	)	$	0.5		$	(0.28	)	$	(0.35	)
	Diluted net income (loss) per common share	$	(0.94	)	$	0.33			(0.28	)	$	(0.35	)
		Fiscal 2013 Quarter Ended
		December 31,			March 31,			June 30,			September 30,
		2012			2013			2013			2013
	Total revenue	$	12,624		$	12,536		$	12,566		$	12,544
	Operating expenses	$	12,287		$	12,614		$	11,795		$	12,373
	Net loss	$	(1,433	)	$	(1,999	)	$	(9,163	)	$	(1,282	)
	Basic and diluted net loss per common share	$	(0.65	)	$	(0.90	)	$	(4.12	)	$	(0.58	)

Organization_Description_of_Bu2

Organization, Description of Business, and Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended		12 Months Ended
In Millions, except Share data, unless otherwise specified	2-May-14	Apr. 08, 2014	Sep. 30, 2014	Apr. 08, 2014	Mar. 20, 2014	Sep. 30, 2013
Organization, Description of Business, and Summary of Significant Accounting Policies
Shares of common stock sold in IPO		6,500,000
Price at which shares of common stock were sold in IPO (in dollars per share)				$8
Period during which underwriters have an option to purchase additional shares of common stock		30 days
Maximum number of additional shares of common stock for which underwriters have an option to purchase at initial public offering price				975,000
Number of shares purchased by underwriters	374,997
Net cash proceeds from the IPO, including proceeds from the partial exercise of the underwriters' option, after underwriting discounts, commissions and issuance costs		$48.50
Issuance of common stock in connection with initial public offering, issuance costs		2.7	2.7
Shares of common stock issued upon conversion of all outstanding shares of convertible preferred stock		3,567,807
Carrying value of outstanding shares of convertible preferred stock reclassified to common stock and additional paid-in capital				57.3
Shares of common stock issued upon conversion of convertible preferred stock and common stock		971,440
Number of shares repurchased		1,077,809
Aggregate repurchase price		$5.20
Authorized shares				155,000,000
Authorized common stock (in shares)			150,000,000	150,000,000		115,000,000
Authorized preferred stock (in shares)				5,000,000
Common stock, par value (in dollars per share)			$0.00	$0.00	$0.00	$0.00
Preferred stock, par value (in dollars per share)				$0.00

Organization_Description_of_Bu3

Organization, Description of Business, and Summary of Significant Accounting Policies (Details 2) (USD $)	0 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 20, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Apr. 08, 2014	Mar. 20, 2014
Reverse Stock Split
Stock split ratio	0.099
Common stock outstanding before reverse stock split (in shares)	19,032,056					19,032,056
Common stock outstanding	1,884,362	18,003,883	1,881,177			1,884,362
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00		$0.00	$0.00
Revenue Recognition
Royalties and profit sharing		$6.70	$7.80	$6.40
Accounts Receivable and Allowance for Doubtful Accounts
Allowance for doubtful accounts		$0	$0
Revenues. | Customer concentration
Concentration of credit risk
Number of partners		4	4
Revenues. | Customer concentration | Four partners
Concentration of credit risk
Concentration risk percentage		95.00%	99.00%	94.00%
Accounts receivable | Credit concentration | Four partners
Concentration of credit risk
Concentration risk percentage		95.00%	100.00%

Organization_Description_of_Bu4

Organization, Description of Business, and Summary of Significant Accounting Policies (Details 3) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
				Transaction
Capital Leases
Number of transactions completed for manufacturing equipment sold to and leased back from the lessor				2
Impairment of Long-Lived Assets
Impairment	$0	$0	$0
Equipment | Minimum
Property and equipment
Useful life	3 years
Equipment | Maximum
Property and equipment
Useful life	8 years
Leasehold improvements | Minimum
Property and equipment
Useful life	3 years
Leasehold improvements | Maximum
Property and equipment
Useful life	15 years

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Financial Liabilities
Preferred stock warrant liability		$560
Recurring basis | Level I
Financial Assets
Total financial assets	36,019	13,342
Recurring basis | Level I | Money market funds
Financial Assets
Total financial assets	36,019	13,342
Recurring basis | Level III
Financial Liabilities
Preferred stock warrant liability		560
Subordinated note embedded derivative liability		7,367
Total financial liabilities		7,927
Recurring basis | Fair Value
Financial Assets
Total financial assets	36,019	13,342
Financial Liabilities
Preferred stock warrant liability		560
Subordinated note embedded derivative liability		7,367
Total financial liabilities		7,927
Recurring basis | Fair Value | Money market funds
Financial Assets
Total financial assets	$36,019	$13,342

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Changes in the fair value of the Level III financial liabilities
Beginning balance			$546
Ending balance	0	7,927	546
Preferred stock warrants
Changes in the fair value of the Level III financial liabilities
Change in fair value	274	14
Extinguishment of preferred stock warrant liability	-834
Subordinated note embedded derivative liability
Changes in the fair value of the Level III financial liabilities
Change in fair value	($7,367)	$7,367

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 3) (Level III, USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Carrying Value
Fair value measurements
Long-term debt	$38,262	$37,413
Convertible notes		9,399
Subordinated note		13,000
Total	38,262	59,812
Fair Value
Fair value measurements
Long-term debt	40,357	37,413
Convertible notes		14,316
Subordinated note		9,508
Total	40,357	61,237
Difference
Fair value measurements
Long-term debt	2,095
Convertible notes		4,917
Subordinated note		-3,492
Total	$2,095	$1,425

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Inventories
Raw materials	$1,268	$2,410
Work in process	898	1,546
Finished goods	632	667
Total inventories, cost	2,798	4,623
Less inventory reserves	-206	-115
Total inventories, net	$2,592	$4,508

Property_and_equipment_Details

Property and equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Property and equipment
Total property and equipment, gross	$26,855	$26,522
Accumulated depreciation and amortization	-14,197	-13,900
Total property and equipment, net	12,658	12,622
Depreciation and amortization of property and equipment	2,230	1,892	1,973
Machinery and equipment
Property and equipment
Total property and equipment, gross	12,242	11,145
Manufacturing equipment acquired under capital leases
Property and equipment
Total property and equipment, gross	2,341	1,825
Transportation equipment
Property and equipment
Total property and equipment, gross	25	25
Furniture and fixtures
Property and equipment
Total property and equipment, gross	995	928
Computer equipment and software
Property and equipment
Total property and equipment, gross	535	401
Leasehold improvements
Property and equipment
Total property and equipment, gross	3,658	3,145
Land
Property and equipment
Total property and equipment, gross	210	210
Construction in progress
Property and equipment
Total property and equipment, gross	$6,849	$8,843

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Intangible assets
Total carrying value	$11,941,000	$11,363,000
Total accumulated amortization	-5,258,000	-4,716,000
Total	6,683,000	6,647,000
Amortization expense	547,000	541,000	512,000
Patents and trademarks
Intangible assets
Total carrying value	10,269,000	9,686,000
Total accumulated amortization	-3,756,000	-3,237,000
Amounts
2015	584,000
2016	584,000
2017	584,000
2018	584,000
2019	584,000
Thereafter	1,480,000
Total	4,400,000
Contract acquisition cost
Intangible assets
Total carrying value	1,672,000	1,677,000
Total accumulated amortization	-1,502,000	-1,479,000
Amortization expense	29,000	65,000	66,000
Amounts
2015	29,000
2016	29,000
2017	29,000
2018	29,000
2019	29,000
Thereafter	25,000
Total	170,000
Contract acquisition cost | Minimum
Intangible assets
Estimated useful lives	4 years
Contract acquisition cost | Maximum
Intangible assets
Estimated useful lives	15 years
Patents
Intangible assets
Amortization expense	500,000	500,000	400,000
Patents | Minimum
Intangible assets
Estimated useful lives	7 years
Patents | Maximum
Intangible assets
Estimated useful lives	20 years
Patents in process
Intangible assets
Total carrying value	$2,100,000	$2,500,000

Notes_Receivable_Related_Parti1

Notes Receivable - Related Parties (Details) (Executive officers, Unsecured note, USD $)	24 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Notes receivable - related Parties
Effective interest rate (as a percent)		2.25%
Maximum
Notes receivable - related Parties
Related party interest income	$1,000
Prime rate
Notes receivable - related Parties
Basis spread on variable rate (as a percent)		-1.00%
Variable rate basis		prime rate

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Sep. 30, 2014	Sep. 30, 2013
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities
Vacation	$1,747	$1,680
Bonus	1,235	900
Warranty liability	284
Employee stock purchase plan liability	305
Legal and professional fees	5	339
Other	432	455
Total accrued liabilities	$4,008	$3,374

Debt_Details

Debt (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Aug. 31, 2012
Debt
Total debt	$63,685,000	$38,262,000
Less current portion, consisting of bank line of credit and long-term debt	4,330,000	107,000
Long-term portion	59,355,000	38,155,000
Bank line of credit
Debt
Total debt	3,873,000
Maximum borrowing capacity			6,000,000
Percentage of eligible accounts receivable considered as base for advances under line of credit facility	80.00%
Effective interest rate (as a percent)	4.25%
Bank line of credit | Minimum
Debt
Monthly interest charge	5,000
Monthly liquidity covenant of net cash on deposit with the commercial bank under the facility	2,000,000
Bank line of credit | Prime rate
Debt
Basis spread on variable rate (as a percent)	0.25%
Variable rate basis	bank prime rate
Long-term debt.
Debt
Total debt	37,413,000	38,262,000
Convertible notes
Debt
Total debt	9,399,000
Subordinated note
Debt
Total debt	$13,000,000

Debt_Details_2

Debt (Details 2) (USD $)	1 Months Ended		12 Months Ended
	Dec. 31, 2012	Aug. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Jul. 13, 2012
			payment
			installment
Long-term Debt
Total long-term debt			$38,262,000	$37,413,000
Less current portion			107,000	457,000
Long-term portion			38,155,000	36,956,000
Term loan agreement
Long-term Debt
Total long-term debt			37,625,000	36,293,000
Unamortized discount			76,000	103,000
Interest rate (as a percent)			15.00%
Face amount					35,000,000
Amount drawn	6,000,000	29,000,000
Number of quarterly installments for repayment of outstanding principal			4
Percentage of cash payment the entity can defer by converting interest due into additional notes			3.50%
Number of quarterly interest payments of which a portion of the interest due can be converted into additional notes under deferral of cash payment			11
Portion of interest due converted into additional notes			2,700,000	1,400,000
Percentage of fee on amount drawn under the facility			1.00%
Notes payable due in April 2015
Long-term Debt
Total long-term debt			96,000	124,000
Monthly payments of principal and interest			3,000	3,000
Interest rate (as a percent)			7.00%	7.00%
Notes payable due in November 2024
Long-term Debt
Total long-term debt			541,000	575,000
Monthly payments of principal and interest			6,000	6,000
Interest rate (as a percent)			7.00%	7.00%
Notes payable due in March 2014
Long-term Debt
Total long-term debt				421,000
Monthly payments of principal and interest				$71,000
Interest rate (as a percent)				2.19%

Debt_Details_3

Debt (Details 3) (USD $)	0 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended	24 Months Ended	1 Months Ended	12 Months Ended
	Apr. 08, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2007	Sep. 30, 2009	Jul. 31, 2012	Sep. 30, 2012	Sep. 30, 2009	Sep. 30, 2014	Jul. 13, 2012
		item	item	item
Debt
Number of investors with right to increase the size of the board of directors and to appoint directors		1
Aggregate repurchase price	$5,200,000
Shares repurchased from the founders	1,077,809
Minimum principal payments on the entity's outstanding debt
2015									107,000
2016									9,439,000
2017									28,296,000
2018									46,000
2019									49,000
Thereafter									325,000
Total		37,413,000							38,262,000
Redeemable Common Stock
Debt
Number of shares repurchased in connection with financing			1,077,809	215,872
Aggregate repurchase price			5,200,000
Number of founders		1	2	2
Convertible notes and warrant purchase agreements
Debt
Proceeds from issuance of debt and warrants					20,000,000
Convertible notes
Debt
Principal amount and accrued interest and a derivative liability	19,400,000
Number of shares converted into common stock	2,036,555
Interest rate (as a percent)	10.00%
Principal amount of debt repaid						10,000,000
Size of the board of directors up to which one investor can increase		11
Number of directors up to which one investor can appoint		6
Percentage of note principal to be issued in the form of common stock warrants							60.00%
Warrant term							5 years
Reduction in additional paid in capital associated with modification of common stock warrants issued		600,000
Convertible notes | Common Stock
Debt
Conversion of debt securities (in shares)			2,036,555
Convertible notes | New series preferred stock
Debt
Conversion of debt securities (in shares)			2,036,555
Term loan agreement
Debt
Interest rate (as a percent)									15.00%
Face amount										35,000,000
Minimum principal payments on the entity's outstanding debt
Total		36,293,000							37,625,000
Subordinated note
Debt
Principal amount and accrued interest and a derivative liability	19,200,000
Number of shares converted into common stock	3,387,146
Interest rate (as a percent)	5.00%
Proceeds from debt issued								13,000,000
Fair value of embedded derivative liability		7,400,000
Number of shares into which debt will automatically be converted in the event of a qualifying IPO or equity financing			3,400,000
Fair value of debt after modification			16,500,000
Reduction in additional paid in capital			$3,500,000
Subordinated note | Common Stock
Debt
Conversion of debt securities (in shares)			3,387,146
Subordinated note | New series preferred stock
Debt
Conversion of debt securities (in shares)			3,387,146
Multiple of preferred stock liquidation preference value			1

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended			0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Aug. 03, 2012
Future minimum lease payments under capital leases, together with the present value of the net minimum lease payments
2015	$897,000
2016	877,000
2017	73,000
Total minimum lease payments	1,847,000
Net minimum lease payments	1,847,000
Less amount representing interest	-185,000
Present value of net minimum lease payments	1,662,000
Less discount related to warrants	-11,000
Capital lease liability	1,651,000
Less current portion	-760,000	-1,029,000
Long-term portion	891,000	1,652,000
Depreciation expense on equipment under capital leases	1,000,000	600,000	600,000
Unrecognized gain on sale of leased assets	0	112,000
Operating Leases
Rental expense on operating leases	1,700,000	1,600,000	1,400,000
Schedule of future minimum lease payments under operating leases that have initial or remaining lease terms in excess of one year
2015	1,284,000
2016	735,000
2017	603,000
2018	611,000
2019	623,000
Thereafter	3,653,000
Total	7,509,000
Pending Litigation | Boudreaux
Loss Contingency
Maximum insurance coverage on the pending suit				10,000,000
Maximum liability of out-of-pocket expense				$50,000

Collaboration_and_Partner_Arra2

Collaboration and Partner Arrangements (Details) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

24 Months Ended

12 Months Ended

24 Months Ended

12 Months Ended

Apr. 08, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2005

Sep. 30, 2008

Oct. 31, 2012

Sep. 30, 2013

Sep. 30, 2007

Sep. 30, 2006

Sep. 30, 2007

Sep. 30, 2004

item

item

item

item

item

Collaboration and partner arrangements

Total revenues

$11,072,000

$10,183,000

$10,717,000

$10,468,000

$12,544,000

$12,566,000

$12,536,000

$12,624,000

$42,440,000

$50,270,000

$42,860,000

Number of shares issued

6,500,000

Collaboration and partner arrangements.

Collaboration and partner arrangements

Total revenues

42,440,000

50,270,000

42,860,000

Collaboration and partner arrangements. | P&G

Collaboration and partner arrangements

Total revenues

11,719,000

11,781,000

7,880,000

License fee revenue

3,000,000

Milestone payments received for the first series of products developed

2,000,000

Shares of common stock issued for payments of patent acquired

125,428

Collaboration and partner arrangements. | Teva

Collaboration and partner arrangements

Total revenues

13,550,000

16,683,000

11,350,000

Number of development programs discontinued by collaboration partner

4

Number of development programs remaining with the collaboration partner

3

Number of development programs resulting in approved products which are currently being marketed by collaboration partner

1

Number of development programs resulting in approved products which collaboration partner is assessing launch strategy and timing

1

Number of other products whose regulatory approval are pending

1

Term of automatic renewals of each commercial agreement

1 year

Collaboration and partner arrangements. | Actavis/Par

Collaboration and partner arrangements

Total revenues

12,971,000

16,551,000

18,139,000

Term of commercial agreement

20 years

Non-cash product revenues associated with the termination of a liability under an agreement

1,800,000

Collaboration and partner arrangements. | Agile

Collaboration and partner arrangements

Total revenues

1,976,000

4,904,000

3,014,000

Amount received from counterparty towards leasehold improvements incurred by the entity

3,500,000

Amount received from counterparty for idle facility charges

1,000,000

600,000

Minimum period commercially produced an agreed-upon quantity of patches

5 years

Collaboration and partner arrangements. | Other

Collaboration and partner arrangements

Total revenues

2,224,000

351,000

2,477,000

Amount will be reimbursed for certain development milestones

4,700,000

Milestone payment received

$500,000

Maximum profit sharing percentage

50.00%

Collaboration and partner arrangements. | Other | Generic transdermal products

Collaboration and partner arrangements

Number of products for which the entity entered into an arrangement

2

Collaboration and partner arrangements. | Barr

Collaboration and partner arrangements

Number of products for which the entity entered into an arrangement

3

Number of separate agreements to develop and commercialize additional products

2

1

3

Collaboration and partner arrangements. | Barr | Generic products

Collaboration and partner arrangements

Number of products for which the entity entered into an arrangement

4

Warrants_Details

Warrants (Details) (USD $)	0 Months Ended	12 Months Ended
	Apr. 08, 2014	Sep. 30, 2014	Sep. 30, 2013	Apr. 08, 2014
Assumptions to estimate the fair value of warrant
Shares of common stock issued upon conversion of Series C convertible preferred stock	971,440
Preferred stock warrants
Warrants
Warrants issued (in shares)			1,739,992
Weighted average exercise price (in dollars per share)	1.88		0.9	1.88
Warrant term		5 years
Number of warrants that expire upon the earlier of five years and the closing of an IPO (in shares)		163,522
Number of warrants with antidilution protection (in shares)			1,380,241
Assumptions to estimate the fair value of warrant
Expected dividend rate (as a percent)			0.00%
Fair value of warrants			$600,000
Stock exercised into shares of common stock using the net exercise provisions in the warrants (in shares)	163,522
Shares of common stock issued upon conversion of Series C convertible preferred stock	1,191
Remaining stock converted into warrants to purchase common stock (in shares)	1,216,719
Amount of preferred stock warrant liability reclassified to stockholders' equity upon exercise of preferred stock warrants		800,000
Preferred stock warrants | Minimum
Assumptions to estimate the fair value of warrant
Remaining contractual term			5 years 26 days
Risk-free interest rate (as a percent)			1.39%
Expected volatility (as a percent)			68.00%
Preferred stock warrants | Maximum
Assumptions to estimate the fair value of warrant
Remaining contractual term			8 years 2 months 27 days
Risk-free interest rate (as a percent)			2.02%
Expected volatility (as a percent)			77.00%
Common stock warrants
Warrants
Warrants issued (in shares)			8,118
Warrants outstanding (in shares)		128,582	1,294,613
Weighted average exercise price (in dollars per share)		1.77	1.95
Assumptions to estimate the fair value of warrant
Remaining contractual term			5 years
Risk-free interest rate (as a percent)			1.41%
Expected volatility (as a percent)			76.00%
Expected dividend rate (as a percent)			0.00%
Common stock value (in dollars per share)			$3.03
Fair value of warrants			$15,000
Stock exercised into shares of common stock using the net exercise provisions in the warrants (in shares)	1,286,495
Shares of common stock issued upon conversion of Series C convertible preferred stock	970,249
Remaining stock converted into warrants to purchase common stock (in shares)	120,464
Common stock warrants | Maximum
Warrants
Warrant term		5 years	5 years

Convertible_Preferred_Stock_Re2

Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Convertible preferred stock
Shares Authorized		65,716,300
Convertible Preferred Stock
Convertible preferred stock
Par value (in dollars per shares)	$0.00
Shares Authorized	5,000,000	65,716,300
Shares Issued	0	36,034,900	36,034,900	36,034,900
Shares Outstanding	0	36,034,900
Aggregate Liquidation Amount		57,261,000
Dividend rate (as a percent)	8.00%
Series A
Convertible preferred stock
Shares Authorized		1,114,100
Original Issue Price (in dollars per shares)		$0.22
Shares Issued		1,114,066
Shares Outstanding		1,114,066
Aggregate Liquidation Amount		490,000
Multiplier used for the calculation of liquidation preference payment		2
Series B
Convertible preferred stock
Shares Authorized		7,602,200
Original Issue Price (in dollars per shares)		$0.88
Shares Issued		7,602,132
Shares Outstanding		7,602,132
Aggregate Liquidation Amount		6,652,000
Multiplier used for the calculation of liquidation preference payment		1
Series B | Maximum
Convertible preferred stock
Multiplier used for distribution of remaining assets or surplus funds		1
Series C
Convertible preferred stock
Shares Authorized		57,000,000
Original Issue Price (in dollars per shares)		$0.92
Shares Issued		27,318,702
Shares Outstanding		27,318,702
Aggregate Liquidation Amount		$50,119,000
Multiplier used for the calculation of liquidation preference payment		2

Convertible_Preferred_Stock_Re3

Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Details 2) (USD $)	Sep. 30, 2014	Apr. 08, 2014	Mar. 20, 2014	Sep. 30, 2013
Common stock
Common shares authorized	150,000,000	150,000,000		115,000,000
Common shares par value (in dollars per share)	$0.00	$0.00	$0.00	$0.00
Common Stock reserved
Issuances under stock option plans (in shares)	2,089,586			1,781,846
Issuances upon exercise of convertible preferred stock warrants (in shares)				3,567,811
Issuances under 2014 employee stock purchase plan (in shares)	310,000
Total shares of common stock reserved	2,528,168			6,816,551
Preferred stock warrants
Common Stock reserved
Issuances upon exercise of warrants (in shares)				172,276
Common stock warrants
Common Stock reserved
Issuances upon exercise of warrants (in shares)	128,582			1,294,618

Convertible_Preferred_Stock_Re4

Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) (Details 3) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 08, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2007
		item	item	item
Repurchases of Common Stock from Founders
Number of shares repurchased	1,077,809
Aggregate repurchase price	$5.20
Redeemable Common Stock
Repurchases of Common Stock from Founders
Number of founders		2	1	2
Number of shares repurchased in connection with financing		1,077,809		215,872
Purchase price under the stock repurchase program (in dollars per share)				$9.26
Number of additional shares authorized to repurchase				215,872
Aggregate repurchase price		$5.20
Remaining number of shares to be repurchased from founder one contingent on approval by the board of directors			132,073
Remaining number of shares to be repurchased from founder two contingent on approval by the board of directors			215,872

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	12 Months Ended			3 Months Ended	0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2014	Mar. 20, 2014
	plan	plan
Stock-based compensation
Number of plans	4	3
Stock-based compensation expense	$1,629,000	$330,000	$66,000
Stock options | Performance-based vesting
Stock-based compensation
Options granted (in shares)		146,024
Awards whose performance-based criteria have been met (in shares)				137,510
Stock-based compensation expense				300,000
Shares Available for Grant
Granted (in shares)		-146,024
Stock Options Outstanding
Granted (in shares)		146,024
2014 Plan
Stock-based compensation
Term of the plan					10 years
Number of shares of common stock reserved under plan for issuance to employees					1,000,000
Maximum annual increase in number of shares issuable by the plan, as a percentage of shares outstanding as of the preceding December 31					4.00%
Corium Plan | Maximum
Stock-based compensation
Term of the plan	10 years
Vesting period	4 years
Corium Plan | Stock options
Stock-based compensation
Options granted (in shares)	573,589	993,327
Shares Available for Grant
Balance at the beginning of the period (in shares)	248,410	231,297	175,811
Additional shares authorized	1,272,277	792,079
Granted (in shares)	-573,589	-993,327
Forfeited / Cancelled (in shares)	2,787	218,361	55,486
Balance at the end of the period (in shares)	949,885	248,410	231,297
Stock Options Outstanding
Balance at the beginning of the period (in shares)	1,528,876	758,414	813,900
Granted (in shares)	573,589	993,327
Exercised (in shares)	-14,650	-4,504
Forfeited / Cancelled (in shares)	-2,787	-218,361	-55,486
Balance at the end of the period (in shares)	2,085,028	1,528,876	758,414
Options exercisable at the end of the period (in shares)	1,240,629
Options vested and expected to vest at the end of the period (in shares)	2,047,439
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$2.22	$3.13	$3.43
Granted (in dollars per share)	$4.86	$2.22
Exercised (in dollars per share)	$2.32	$2.32
Forfeited / Cancelled (in dollars per share)	$3.30	$5.93	$6.67
Balance at the end of the period (in dollars per share)	$2.92	$2.22	$3.13
Options exercisable at the end of the period (in dollars per share)	$2.39
Options vested and expected to vest at the end of the period (in dollars per share)	$2.91
Weighted Average Remaining Contractual Life
Balance at the end of the period	7 years 7 days	7 years 2 months 19 days	5 years 2 months 12 days
Options exercisable at the end of the period	5 years 10 months 21 days
Options vested and expected to vest at the end of the period	7 years
Aggregate Intrinsic Value
Balance at the end of the period	6,710,000	1,287,000
Options exercisable at the end of the period	4,647,000
Options vested and expected to vest at the end of the period	6,589,000
Additional disclosures
Exercise price, minimum(in dollars per share)	$2.12
Exercise price, maximum(in dollars per share)	$8.18
Weighted average grant date fair value of options granted (in dollars per share)	$8.03	$1.31
Assumptions used in estimating weighted average fair value of the options granted
Risk-free interest rate, minimum	1.61%	0.70%
Risk-free interest rate, maximum	2.25%	1.38%
Expected volatility, minimum	63.00%	71.00%
Expected volatility, maximum	74.00%	75.00%
Expected dividend rate (as a percent)	0.00%	0.00%
Corium Plan | Stock options | Minimum
Assumptions used in estimating weighted average fair value of the options granted
Expected term (in years)	5 years 3 months 7 days	2 years 6 months
Corium Plan | Stock options | Maximum
Assumptions used in estimating weighted average fair value of the options granted
Expected term (in years)	6 years 29 days	6 years 29 days
StrataGent Plan | Stock options
Stock-based compensation
Options granted (in shares)	0	0	0
Shares Available for Grant
Granted (in shares)	0	0	0
Forfeited / Cancelled (in shares)		9,233
Stock Options Outstanding
Balance at the beginning of the period (in shares)	4,560	35,477	97,276
Granted (in shares)	0	0	0
Exercised (in shares)		-21,684	-61,799
Forfeited / Cancelled (in shares)		-9,233
Balance at the end of the period (in shares)	4,560	4,560	35,477
Options exercisable at the end of the period (in shares)	4,560
Options vested and expected to vest at the end of the period (in shares)	4,560
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$0.71	$0.20	$0.20
Exercised (in dollars per share)		$0.10	$0.20
Forfeited / Cancelled (in dollars per share)		$0.20
Balance at the end of the period (in dollars per share)	$0.71	$0.71	$0.20
Options exercisable at the end of the period (in dollars per share)	$0.71
Options vested and expected to vest at the end of the period (in dollars per share)	$0.71
Weighted Average Remaining Contractual Life
Balance at the end of the period	2 years 1 month 17 days	3 years 1 month 17 days	1 year 9 months 26 days
Options exercisable at the end of the period	2 years 1 month 17 days
Options vested and expected to vest at the end of the period	2 years 1 month 17 days
Aggregate Intrinsic Value
Balance at the end of the period	25,000	11,000
Options exercisable at the end of the period	25,000
Options vested and expected to vest at the end of the period	$25,000
Additional disclosures
Exercise price, minimum(in dollars per share)	$0.18
Exercise price, maximum(in dollars per share)	$0.88

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	12 Months Ended			0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Mar. 20, 2014
Stock-Based Compensation
Stock-based compensation expense	$1,629,000	$330,000	$66,000
2014 Employee Stock Purchase Plan
Stock-Based Compensation
Number of shares of common stock reserved under plan for issuance to employees				310,000
Term of the plan				10 years
Maximum annual increase in number of shares issuable by the plan, as a percentage of shares outstanding as of the preceding December 31				1.00%
Maximum number of shares to be issued over the term of the plan				4,000,000
Shares issued under the plan	0
Offering period				2 years
Period of purchase windows during each offering period	6 months
Purchase price of common stock of the lower of the fair market value of the Company's common stock (as a percent)	85.00%
Stock-based compensation expense	$253,000
Assumptions used in estimating weighted average fair value of the shares expected to be purchased
Expected volatility, minimum	42.00%
Expected volatility, maximum	55.00%
Risk-free interest rate, minimum	0.07%
Risk-free interest rate, maximum	0.52%
Expected dividend rate (as a percent)	0.00%
Percentage of Company's IPO price for the first offering period that the fair value of shares of common stock is based on	85.00%
2014 Employee Stock Purchase Plan | Minimum
Assumptions used in estimating weighted average fair value of the shares expected to be purchased
Expected term (in years)	7 months 17 days
2014 Employee Stock Purchase Plan | Maximum
Assumptions used in estimating weighted average fair value of the shares expected to be purchased
Expected term (in years)	2 years 1 month 17 days

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 3) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Employee stock-based compensation expense
Stock-based compensation	$1,629,000	$330,000	$66,000
Additional Disclosure
Unrecognized employee compensation cost, net of estimated forfeitures	4,100,000
Weighted-average period over which unrecognized compensation cost is expected to be recognized	3 years 1 month 6 days
Cost of product revenues
Employee stock-based compensation expense
Stock-based compensation	188,000	35,000
Cost of contract research and development revenues
Employee stock-based compensation expense
Stock-based compensation	196,000	21,000
Research and development
Employee stock-based compensation expense
Stock-based compensation	151,000	39,000
General and administrative
Employee stock-based compensation expense
Stock-based compensation	$1,094,000	$235,000	$66,000

Product_Recall_Liability_Detai

Product Recall Liability (Details) (USD $)	12 Months Ended			36 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2010
				item
Product recall liability
Revised combined remaining liability	$3,710	$4,832	$5,000
Changes to the product recall liability
Beginning balance	4,832	5,000	8,623
Non-cash reductions in recall liability prior to settlement			3,041
Gain on settlement of recall liability			-582
Payment of settlement liability	-1,122	-168
Ending balance	$3,710	$4,832	$5,000
Actavis
Product recall liability
Number of voluntary recalls of certain lots and strengths of Fentanyl TDS				2

Product_Liability_Details

Product Liability (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Changes to the product liability reserve
Beginning balance	$90	$720	$500
Settlement payments		-1,300	-307
Expense (income)	-5	670	527
Ending balance	$85	$90	$720

Net_Loss_and_Net_Loss_per_Shar2

Net Loss and Net Loss per Share Attributable to Common Stockholders (Details) (USD $)	3 Months Ended				12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Net Loss and Net Loss per Share Attributable to Common Stockholders
Net loss attributable to common stockholders, basic and diluted (in dollars)					($9,912)	($13,877)	($5,443)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted					10,043,640	2,222,981	2,200,727
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	($0.58)	($4.12)	($0.90)	($0.65)	($0.99)	($6.24)	($2.47)
Convertible Preferred Stock
Anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders						3,567,811	3,567,811
Stock options
Anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders					2,089,586	1,781,844	1,025,188
Shares authorized
Anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders					310,000
Common stock warrants
Anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders					128,582	1,294,618	1,269,634
Preferred stock warrants
Anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders
Number of anti-dilutive securities excluded from calculation of diluted net loss per share attributable to common stockholders						172,276	172,276

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
	item
Income Taxes
Number of jurisdiction under which Company operates	1
Reconciliation of the tax expense (benefit) computed at the statutory federal rate and the Company's tax expense (benefit)
Income tax benefit - computed as 34% of pretax loss	($3,370,000)	($4,717,000)	($1,851,000)
Effect of nondeductible expenses	695,000	695,000	881,000
State and local income tax expenses	1,000	1,000	-6,000
Valuation allowance	2,403,000	4,270,000	876,000
Effect of tax credits and other	-13,000	-50,000	-1,000
State deferred taxes	285,000	-188,000	75,000
Other		-10,000	19,000
Total	1,000	1,000	-7,000
Statutory federal rate (as a percent)	34.00%
Deferred tax assets:
Net operating loss carryforward	26,279,000	21,491,000
Depreciation	694,000	720,000
Accrued expenses	1,686,000	1,782,000
Research and development tax credit	1,982,000	1,970,000
State deferred taxes	1,651,000	1,965,000
Subordinated debt embedded derivative		2,505,000
Other	1,508,000	801,000
Gross deferred tax assets	33,800,000	31,234,000
Valuation allowance	-33,518,000	-30,997,000
Net deferred tax assets	282,000	237,000
Deferred tax liabilities:
Other	-282,000	-237,000
Gross deferred tax liabilities	-282,000	-237,000
Federal
Operating loss carryforwards
Net operating loss carryforwards	77,300,000
State
Operating loss carryforwards
Net operating loss carryforwards	$12,800,000

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Income Taxes
Increase in valuation allowance	$2.50	$4.30
Credit carryforwards
Uncertain tax positions	0
Interest expense or penalties related to unrecognized tax benefits	0
Federal
Credit carryforwards
Credit carryforwards amount	2
State
Credit carryforwards
Credit carryforwards amount	$1.40

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Employee Benefit Plan
Contributions amount	$93,000	$90,000	$80,000

Segment_and_EnterpriseWide_Inf1

Segment and Enterprise-Wide Information (Details)	12 Months Ended
	Sep. 30, 2014
	item
Segment and Enterprise-Wide Information
Number of business activities	1
Number of segment managers held accountable for operations, or operating results for levels or components	0

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Selected quarterly results from operations
Total revenues	$11,072	$10,183	$10,717	$10,468	$12,544	$12,566	$12,536	$12,624	$42,440	$50,270	$42,860
Operating expenses	15,869	13,580	11,511	11,530	12,373	11,795	12,614	12,287	52,490	49,069	43,670
Net income (loss)	($6,367)	($4,981)	$3,534	($2,098)	($1,282)	($9,163)	($1,999)	($1,433)	($10,050)	$1,201	($810)
Basic net income (loss) per common share (in dollars per share)	($0.35)	($0.28)	$0.50	($0.94)
Diluted net income (loss) per common share (in dollars per share)	($0.35)	($0.28)	$0.33	($0.94)
Basic and diluted net loss per common share (in dollars per share)					($0.58)	($4.12)	($0.90)	($0.65)	($0.99)	($6.24)	($2.47)

Subsequent_Events_Details

Subsequent Events (Details) (Term loan agreement, USD $)	12 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Nov. 30, 2014	Jul. 13, 2012
	installment	installment
Subsequent events
Face amount			$35
Interest rate (as a percent)	15.00%
Number of quarterly installments for repayment of outstanding principal	4
Subsequent event
Subsequent events
Face amount		$45
Interest rate (as a percent)		15.00%
Maximum percentage of interest that can be converted each quarter into PIK notes		3.50%
Number of quarterly installments for repayment of outstanding principal		4